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Recent statistics report a global blind population of 32.4 million and 191 million people with vision 
impairment, of which more than 90% of the world’s visually impaired live in developing countries. 
Glaucoma, the third leading cause of blindness in Africa (after cataract), is responsible for 
approximately 15% of blindness in the continent, requiring early detection, but goes undiagnosed in 
developing countries because of lack of awareness of the disease and its effects. Screening methods are 
not always affordable and relatively inaccessible in most developing countries, posing a barrier to 
identifying people at risk of glaucoma blindness. 
The Humphrey’s Visual Field Analyser (HVFA), considered as the gold standard in assessing visual 
fields, is not suited to mass screening due to cost, portability, test time, physical testing requirements 
among other issues, thereby making it inconvenient for mass screening programmes. These 
shortcomings motivated the development of the Moorfield’s Motion Displacement Test (MMDT), a 
new portable visual field instrument, at the Moorfield’s Eye Hospital in London. 
Aim: To determine the agreement and sensitivity between the Humphrey’s Visual Field Analyser 
(HVFA) and the Moorfield’s Motion Displacement Test (MMDT). 
Methods: The study followed a comparative design based on simple random sampling, comprising two 
hundred and seven subjects. Of the total number of subjects included in the study, the glaucoma group 
comprised sixty-two subjects, whilst the control group comprised one hundred and forty-five subjects. 
A total of 293 eyes were included in the study, of which 94 eyes were glaucomatous (case) and 199 
eyes were non-glaucomatous (control), of participants who were selected via chart review from two 
district hospitals in KwaZulu Natal (KZN), South Africa; McCords Provincial Eye Hospital (case) and 
Prince Mshiyeni Memorial Hospital (control). Both eyes were tested using the HVFA and the MMDT 
instruments. All subjects were asked to complete a questionnaire prior to and after testing on both 
instruments.  
Results: Non-parametric tests were used because results were not normally distributed. The diagnostic 
accuracy of the MMDT was high in terms of test sensitivity (100%), but performed less well in terms 
of specificity (63.3% and 65.3%) for case and control participants respectively. Despite the low 
specificity, there was a high level of similarity and a faster testing time (for both groups) in detecting 
glaucomatous visual field defects on the MMDT compared with the HVFA. A significant number of 
participants (83.5 %) across the different race groups, preferred the MMDT over the HVFA, and found 
the use of the mouse over a push button to be easier (74.5% across all race groups). Majority of 
participants (80.5%) reported focusing on a central white dot seemed more comfortable than a central 
amber light and found anxiety levels reduced whilst using the MMDT.  
xiii 
 
Conclusion: The high sensitivity and design advantages of the MMDT for population screening may 
help improve glaucoma case finding in the community, and thereby facilitate earlier treatment and better 
health outcomes for those affected. The specificity issue should be addressed, however, to avoid service 
delivery problems associated with unnecessary false positive referrals. 




CHAPTER  1: Introduction  
1.1 Background 
In 2015, it was estimated that of the global population, 36 million people were blind, 216.6 million had 
moderate to severe visual impairment and 188.5 million had mild visual impairment (Bourne et al., 
2017) with more than 90% of the visually impaired living in developing countries (Resnikoff et al., 
2008). Most of the burden of vision loss lies amongst those individuals 50 years and older, and although 
the prevalence decreased worldwide since the past 20 years, the number of blind and vision impaired 
people did not decrease, due to the rapid increase in the older adult population (Stevens et al., 2013).    
Along with the increasing life expectancy, age-related co-morbid conditions increased as well which 
included irreversible ophthalmic diseases, affecting the overall quality of life (Loughman et al., 2013).  
 
The most common causes of blindness and vision impairment worldwide, according to studies done 
over the past 20 years, are reported to be: cataract, glaucoma, macular degeneration, diabetic 
retinopathy, trachoma and uncorrected refractive error, and are classified as avoidable vision loss 
(Stevens et al., 2013). Naidoo et al (2013) in a study in the Lower Tugela Health District in KwaZulu 
Natal, South Africa, reported that the main causes of vision impairment (considered to be potentially 
blinding diseases) were: refractive error (44.5%); cataract (31.2%); glaucoma (6.0%); hypertensive 
retinopathy (4.1%) and diabetic retinopathy (4.1%). Those conditions linked to the cause of bilateral 
blindness were: cataract (54.8%); refractive error (12.9%); glaucoma and hypertensive retinopathy 
(6.4%), with diabetic retinopathy and other ocular conditions such as corneal scarring and retinal 
coloboma accounting for 3.2% of bilateral blindness (Naidoo et al., 2013). It was also found that 9.7% 
of bilateral blindness were caused by Albinism, coloboma and age-related macula degeneration (Naidoo 
et al., 2013). 
 
In a study in Cape Town, South Africa, posterior segment diseases (including glaucoma) were found to 
be the leading cause of blindness, accounting for 65% of blindness (Cockburn et al., 2012).  Age related 
macular degeneration (ARMD), optic atrophy, trauma and macula hole made up the remaining posterior 
segment diseases (Cockburn et al., 2012).  Glaucoma is the third  leading cause of blindness in Africa, 
after cataract, and is responsible for approximately 15% of blindness in the continent (Lawrence and 
Budenz, 2013).  A significant challenge to blindness prevention programmes is the management of 
glaucoma, among other ocular diseases, since it requires significantly more resources than, for example, 
cataract (Cockburn et al., 2012).  
 
In developing countries, the challenge is exacerbated as there are no primary care screening strategies 
in place and the lack of equipment and other resources renders eye health care services inaccessible to 
the majority (Loughman et al., 2013). The costs of standard methods for screening, including 
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computerised perimetry, are not affordable and are relatively inaccessible in most developing countries 
(Ong et al., 2014). Therefore, there is a great need for more affordable and faster methods (Govender 
et al., 2015). Compliance with medical treatment is related to many factors, some of which include the 
asymptomatic nature of the disease and the level of education and socio-economic status of the patient 
(Leite et al. 2011). 
 
Africa has 15% of the world’s visually impaired and just over half (50.9%) of the world’s poor.  It is 
believed that poverty and eye health are interrelated (Jaggernath et al., 2014).  In addition to the 
economic impact, educational opportunities and quality of life are also affected (Stevens et al., 2013).  
Although treatment for glaucoma is effective, it requires early detection (community based screening), 
lifelong monitoring and a great level of adherence to therapy to prevent vision loss (Cockburn et al., 
2012).  Therefore, eye care systems that address chronic eye diseases with rehabilitation and support 
services need to be urgently developed (Pascolini and Mariotti, 2010). 
 
If glaucoma is left undiagnosed there are many activities of daily living that are affected, with its 
consequent socio-economic effects (World Health Organisation, 2006). These include difficulty in 
reading and writing, mobility and colour discrimination (Taylor and Keeffe, 2001; Rong-jiang et al., 
2011). Direct costs of blindness include treatment of eye diseases, pharmaceuticals and research and 
administration.  Indirect costs include lost earnings of the visually impaired, state grants, cost of visual 
aids and caregivers, equipment, home modifications and rehabilitation (World Health Organisation, 
2006). 
 
Visual field assessment is important in the diagnosis of glaucoma and the Humphrey’s Visual Field 
Analyser (HVFA) is one of the instruments used (Alencar and Medeiros, 2011).  The HVFA is regarded 
as the gold standard for the assessment of visual fields (Choplin et al. 1998).  Although recent 
developments have seen the advent of more sophisticated psychophysical visual function tests, visual 
field instruments remain expensive and relatively inaccessible in rural or underdeveloped areas (Ong et 
al., 2014).  The acknowledgement of these limitations has initiated the development of more affordable 
instruments for visual field testing (Broadway, 2012) which can be more easily utilised and accessed in 
the developing world context (Asana et al., 2013) 
 
In the 1980s, Professor Fitzke (Institute of Ophthalmology, London) developed the original Motion 
Displacement Test (MDT) which was found to be a detector of glaucomatous visual field loss 
(Moorfield’s Eye Hospital: NHS Foundation Trust, 2008). Evidence of elevated motion displacement 
threshold was shown in some areas of the visual field not usually affected on standard automated 
perimetry (SAP) assessment and the MDT proved to be resistant to the effect of media opacity (Ong et 
al., 2014).  
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These properties provided the rationale for further development of the test and since 1999, new visual 
field testing equipment called the Moorfields Motion Displacement Test (MMDT) has been under 
development.  The MMDT is a multi-location test, presented on a computer screen with 32 line stimuli; 
each scaled by estimate of retinal ganglion cell density (Moorfield’s Eye Hospital: NHS Foundation 
Trust, 2008). However, its accuracy in comparison to the HVFA has not yet been established.  The 
purpose of the study was, therefore, to compare the visual field defects, if any, obtained by the MMDT 
to that obtained with the HVFA in diagnosed glaucoma subjects.   
 
1.2 Research questions, aim and objectives 
1.2.1 Research questions 
Primary research question: Does the diagnostic accuracy of the MMDT relative to the HVFA warrant 
its use for mass glaucoma screenings in the community?  
Secondary research questions: 
1.2.1.1 Do gender, age and race affect the testing time using both the HVFA and the MMDT? 
1.2.1.2 Are gender, age and race associated with the preference of fixation target (light or dot)? 
1.2.1.3 Are gender, age and race associated with the preference for fixation target indicator 
 (button or mouse) between HVFA and MMDT? 
1.2.1.4 Are gender, age and race associated with the selection of visual field instrument? 
1.2.1.5 Are gender, age and race associated with the level of anxiety experienced with the 
HVFA and MMDT? 
1.2.2 Overall Aim 
The aim of this study was to assess the diagnostic accuracy, acceptability, and usability of the 
Moorfields Motion Displacement Test (MMDT) in comparison with the gold standard Humphreys 
Visual Field Analyser (HVFA) as a tool for community glaucoma screening.  
  
1.2.3 Specific Objectives 
The specific objectives of the study were: 
1.2.3.1 To determine the diagnostic performance of the MMDT relative to the gold standard HVFA 
1.2.3.2 To determine the level of similarity in findings between the HVFA and MMDT 
1.2.3.3 To explore the influence of demographic factors such as age, gender and race on the usability 
and acceptability of/preference for the MMDT device over HVFA, including test time, fixation, target 





1.2.4.1 H0: The distribution of test duration using the Moorfields Motion Displacement Test (MMDT) 
is the same across categories of race, gender and age 
1.2.4.2 H0: The distribution of test duration using the HVFA is the same across categories of race, gender 
and age 
1.2.4.3 H0: There is no significant correlation between the results obtained with the MMDT as compared 
to that found with the HVFA 
1.2.4.4 H0: The level of similarity between the MMDT and HVFA does not validate the MMDT be used 
as a screening or diagnostic tool for patients with visual field defects 
1.2.4.5 H0: The association between gender, age and race is the same regarding the preference for 
fixation target (light or dot) 
1.2.4.6 H0: The association between gender, age and race is the same regarding the preference for 
fixation target indicator (button or mouse) between HVFA and MMDT  
1.2.4.7 H0: The distribution of the selection of preferred visual field instrument is the same across 
categories of gender, age, and race 
1.2.4.8 H0: The level of anxiety experienced with the HVFA and MMDT is the same across categories 




Glaucoma is an important cause of vision impairment and blindness. Once diagnosed, however, it can 
be effectively managed using medical and surgical interventions. These are most effective when the 
condition is diagnosed early. A large number of patients with glaucoma remain undiagnosed. The 
condition is asymptomatic in the early stages, so detection relies on effective community-based 
screening. Due to a lack of affordable and accessible screening and diagnostic tools, many sufferers 
present to eye care facilities when the condition is advanced and irreversible vision loss has already 
occurred. Treatment at this stage is challenging and the risks for vision impairment and blindness are 
high even with treatment. The development of a user-friendly, accessible and affordable device such as 
the MMDT for mass population glaucoma screening offers the potential, therefore, to facilitate better 
community detection of glaucoma, allow earlier treatment initiation and improved health outcomes that 
benefits patients, families and society in general. The purpose of the current study is to explore the 
feasibility of the MMDT device for glaucoma screening by examining its diagnostic performance and 
user experience compared to the gold standard HVFA test. 
 
Conclusion 
This chapter focuses on the current global issue of glaucoma, being the third leading cause of worldwide 
blindness. It also addresses the urgent need for more affordable, accessible, and portable visual field 
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instruments, considering most of the burden of visual impairment lies in developing countries. By 
allowing for an earlier detection and diagnosis, the overall health and socio-economic impact of 
glaucoma and its role in irreversible blindness can be significantly reduced. In addition to the feasibility, 
the MMDT is also simple to perform, therefore technical staff can be trained on screening the 







CHAPTER 2: Literature Review 
 
The following chapter is a detailed literature review addressing glaucoma and its subtypes, the risk 
factors involved as well as important glaucoma prevalence and vision impairment data. It also highlights 
the barriers to accessing health care in South Africa, which forms part of a much larger issue in a 
developing world context. Also included are the current types of visual screening instruments and a 
discussion of the Moorfield’s Motion Displacement Test (MMDT). 
 
2.1. Glaucoma in South Africa 
2.1.1 Definition of glaucoma 
The evolved definition of glaucoma according to Casson et al. (2012) is as follows: 
‘Glaucoma describes a group of ocular disorders of multifactorial aetiology united by a clinically 
characteristic optic neuropathy with potentially progressive, clinically visible changes at the optic 
nerve head (ONH), comprising focal or generalized thinning of the neuroretinal rim with excavation 
and enlargement of the optic cup.’  
In 2004, 3.9% of the total global burden of disease was caused by vision loss (Stevens et al., 2013). 
Bourne et al. (2013) reported that, of the global population with vision loss, 32.4 million people are 
blind and 191 million people with vision impairment, with more than 90% of the visually impaired 
living in developing countries (Resnikoff et al., 2008). In addition to this burden, increasing life 
expectancy and its link to age-related co-morbid conditions (including irreversible ocular diseases) have 
affected the overall quality of life (Loughman et al., 2013).  
Globally, glaucoma is the second highest cause of avoidable blindness after cataract (Bourne et al., 
2013) and affects around 2% of the adult population 50 years and older (Brusini et al., 2005). Glaucoma 
is described as a characteristic optic neuropathy with retinal ganglion cell (RGC) atrophy and retinal 
nerve fibre layer (RNFL) damage, resulting in clinically visible changes at the optic nerve head, as well 




2.1.2 Types of glaucoma 
 
 
Figure 2.1 Schematic representation of types of glaucoma 
Glaucoma can broadly be classified (Figure 2.1) as: primary, secondary (Rudnicka and Owen, 2007) 
and infantile (Schacknow and Samples, 2010), however, several different types can occur. 
 
2.1.2.1 Primary glaucoma 
In primary glaucoma, the glaucomatous damage isn’t associated with any other ocular disorder and 
includes the following (Rudnicka and Owen, 2007):  
2.1.2.1.(a) Primary open angle glaucoma (POAG)  
Primary open angle glaucoma presents most often as an adult onset glaucoma, is generally bilateral and 
asymmetric and produces structural changes to the optic nerve head and visual field, regardless of the 
level of IOP (Rudnicka and Owen, 2007).  Like the name suggests, the anterior chamber angle remains 
unobstructed, however the drainage of aqueous humour is compromised (Rudnicka and Owen, 2007). 
It is also referred to as a chronic ‘simple’ glaucoma (Kanski, 2007), which can further be subdivided 
into:  
-Normal tension glaucoma which includes those with Glaucomatous Optic   Neuropathy (GON) 
but an IOP within the normal range (between 11-21mmHg) and; 




2.1.2.1.(b)Primary angle closure glaucoma (PACG) 
In this category of glaucoma, anatomical irido-trabecular contact (due to either anterior or posterior 
forces) causes the angle to be acutely or chronically narrowed (Casson et al., 2012) 
2.1.2.2 Secondary glaucoma 
Increased IOP due to a secondary cause, example: cataract, uveitis, trauma and disorders affecting the 
drainage and structure of the anterior chamber angle, result in a secondary glaucoma (Rudnicka and 
Owen, 2007). This type of glaucoma is further subdivided into: 
2.1.2.2.(a) Secondary open-angle glaucoma is glaucomatous optic neuropathy due to a 
secondary cause in the presence of an unobstructed angle (Casson et al., 2012), which can occur 
pre-trabecular, trabecular or post-trabecular (Kanski, 2007).   
2.1.2.2.(b) Secondary angle-closure glaucoma is characterised by glaucomatous optic 
neuropathy with irido-trabecular contact of a pathological cause (Casson et al., 2012).  Aqueous 
outflow is impaired secondary to the apposition between the peripheral iris and the trabecular 
meshwork (Kanski, 2007). 
Examples of secondary glaucoma include, but are not limited to; uveitic, neovascular, 
pseudoexfoliation, pigmentary and traumatic glaucoma (Kanski, 2007).  
2.1.2.3 Infantile primary congenital glaucoma (PCG) 
Amongst infants and older children, the most common primary glaucoma seen is infantile primary 
congenital glaucoma (PCG). It is hereditary and secondary to abnormal development of the filtration 
angle (Schacknow and Samples, 2010). 
 
2.1.3 The trabecular meshwork and its significance in glaucoma 
The anterior chamber angle is an angular space bounded anteriorly by the posterior aspect of the cornea 
and posteriorly by the anterior aspect of the iris and part of the ciliary body and contains aqueous 
humour, produced by the ciliary body (Raluca et al., 2015). At the angle of the anterior chamber is the 
trabecular meshwork, which is a sieve-like structure through which 90% of the aqueous humour leaves 
the eye (Kanski, 2007). Aqueous outflow occurs via two main channels, mainly trabecular and 
uveoscleral and IOP is determined by the rate of aqueous secretion and rate of outflow (Weinreb et al. 
2014). Retinal ganglion cell death is related to the level of IOP and raised IOP secondary to reduced 
aqueous outflow through the filtration angle is an important risk factor for glaucoma (Kanski, 2007; 




2.1.4 Risk factors for glaucoma  
Research studies have identified possible (however, not entirely conclusive) risk factors for glaucoma 
which include: ocular, systemic, environmental and molecular genetic risk factors (Janssen et al., 2013). 
The following are important risk factors for evaluation of glaucoma: older age, family history of 
glaucoma, being of African ethnicity, use of topical or systemic corticosteroids and high IOP (Weinreb 
et al. 2014). The above risk factors are briefly explained below: 
2.1.4.1 Intraocular Pressure (IOP) and central corneal thickness (CCT) 
Intraocular pressure is an important risk factor (Racette et al., 2003), however, it is not a pre-requisite 
(Rudnicka and Owen, 2007).  Some research states that patients with an elevated IOP are usually at risk 
for POAG (Montgomery and Yim, 2007), but whilst the accepted normal range of IOP is 10- 21mmHg, 
with a mean of 16mmHg, this range is debatable as some patients with elevated IOP never develop 
glaucoma, whilst some with normal IOP readings show glaucomatous damage (Racette et al., 2003).  
In addition to the above, central corneal thickness (CCT) was also shown to be a risk factor, with 
patients having a thinner CCT being at a higher risk of ocular hypertension progressing to glaucoma 
(Schacknow and Samples, 2010). 
2.1.4.2 Genetic predisposition 
According to a study, up to 50% of POAG patients reported a positive family history for the disease 
(Racette et al., 2003). Complex diseases, like glaucoma, collectively manifest heritability of several 
individual traits, therefore studies are focused on targeting the genes responsible for each individual 
trait (Gupta et al., 2018). The characteristic optic neuropathy responsible for almost all classes of 
glaucoma is the reason for the growing interest in studies which identify genetic markers responsible 
for apoptosis of retinal ganglion cells (RGC’s) at the optic nerve (Gupta et al., 2018). 
 
2.1.4.3 Systemic illnesses   
Whether Diabetes Mellitus is related to the diagnosis of POAG is still being investigated, however, 
there has been evidence suggesting diabetes is associated with elevated IOP (Racette et al., 2003).  
Despite no causal relationship between POAG and systemic hypertension having yet been established, 
studies report systemic blood pressure is closely related to IOP, which is an important risk factor in 
glaucoma development (Racette et al., 2003)(Wong and Mitchell, 2007).  
 
2.1.4.4 Race and gender 
Among individuals of African origin, the disease onset is usually earlier and progresses more rapidly 
as compared to other race groups (Buhrmann et al., 2000). It was also found that the prevalence of 
POAG among patients of African origin was independent of refractive error (Racette et al., 2003). The 
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susceptibility of the disease was also found to be higher in males than in females (Rotchford and 
Johnson, 2002; Kapetanakis et al., 2016).  
2.1.4.5 Environmental risk factors for glaucoma 
There have been a few investigations into the development of POAG through effects on IOP and/or the 
rate of retinal ganglion cell apoptosis (Foster et al., 2002; Pasquale and Kang, 2009). The following 
have been reported to play a role in an increase in IOP: playing high resistant wind instruments, drinking 
coffee, engaging in certain yoga positions, wearing tight neck ties and weight lifting, whilst general 
physical exercise has shown a resultant decrease in IOP (Pasquale and Kang, 2009; Wiggs, 2012; Lin 
et al., 2017). The predisposition to glaucoma development as a result of the related IOP increase from 
the above activities has not yet been studied (Pasquale and Kang, 2009). 
Among those mentioned above, certain nutritional and lifestyle factors have also been identified as 
influencing POAG development, such as dietary fat and antioxidant intake, post-menopausal hormone 
use, gene- environment interaction (specifically hormone replacement therapy and Nitric Oxide 
Synthase 3 (NOS3) and smoking (Pasquale and Kang, 2009; Wiggs, 2012). Apart from direct 
influences, those residing in Northern latitudes were at a higher risk of developing exfoliation syndrome 
glaucoma as ambient temperature and sun exposure are triggers, although other features of Northern 
latitude exposures, such as vitamin D metabolism could contribute as well (Wiggs, 2012). By 
identifying the primary preventive measures incurred by POAG, the burden of visual disability 
(including the economic consequences of glaucoma) can be reduced (Pasquale and Kang, 2009). 
2.1.4.6 Epigenetics role in glaucoma 
Epigenetics has been described as gene expression regulation without changing the primary DNA 
sequence (Wiggs, 2012; He et al., 2013). It was found that the application of Trichostatin A (TSA) and 
valproic acid (histone deacetylase inhibitors) can reduce the loss of retinal ganglion cells and enhance 
axonal regeneration after optic nerve damage, suggesting abnormal histone acetylation/deacetylation 
could possibly be related to retinal ganglion cell loss in glaucoma (He et al., 2013).  Recently, the 
CDKN2BAS locus was found to be associated with POAG and optic nerve cup-disc ratio (CDR), which 
is a genomic region that appears to be regulated by epigenetic mechanisms, however, although 
investigations in this area are at fairly recent stages, they could have a significant impact on future 
therapeutic approaches (Wiggs, 2012).  
 
2.1.5 Prevalence and statistics of glaucoma 
The leading cause of irreversible blindness globally, is glaucoma, with a prevalence of 3.54%, of which 
POAG and PACG, among those aged 40-80 years old, accounted for 3.05% and 0.50% respectively 
(Tham et al., 2014). In 2010, 60.5 million people were affected by POAG and PACG globally, with 
Africa having the highest prevalence of POAG (Gilmour-White et al., 2015) and Asia having the highest 
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prevalence of PACG (Tham et al., 2014). The most prevalent of the several types of glaucoma was 
found to be POAG (Rudnicka and Owen, 2007) having approximately 53 million sufferers worldwide 
(Kapetanakis et al., 2016) - about three quarters of all glaucoma cases (Kapetanakis et al., 2016). 
However, secondary glaucoma does not have much research in its category, which is believed to 
represent approximately 20% of all types of glaucoma, and includes those caused by the following 
processes: neovascularisation, uveitic, lens related and trauma (Foster et al., 2002). Buhrmann et al. 
(2000) found a prevalence of 0.06% and 0.09% of secondary OAG and secondary ACG respectively in 
East Africa. In 2013, Africa had the second highest number of glaucoma cases, with 8.3 million of the 
world’s total 64.3 million cases (Tham et al., 2014).  The Temba glaucoma study, a population-based 
cross-sectional survey in urban South Africa, reported a prevalence of 5.3% of all types of glaucoma in 
South Africa, of which, the most common being POAG which accounted for 2.9% in South Africa 
(Rotchford et al., 2003). These findings were similar to the findings of Kyari et al. (2015), who found 
a prevalence of 5.02% of all types of glaucoma in Nigeria. 
  
In the Rapid assessment of avoidable blindness in the Northern eThekwini district of KwaZulu-Natal 
Province, South Africa (RAAB Study), Govender et al. (2015) found of the 1.9% of bilaterally blind 
individuals, 24.1% was due to glaucoma. The adjusted prevalence of all glaucoma types in individuals 
in KwaZulu-Natal of Zulu ethnic origin was 4.5%, occurring most in individuals 80 years and older 
(Rotchford and Johnson, 2002). Of all subjects with glaucoma, 58% had become blind in at least one 
eye and, 87% of those subjects with POAG had not been previously diagnosed (Rotchford et al., 2003). 
The main concern is that there is a high prevalence of glaucoma sufferers.  Almost half are undiagnosed 
in the developed world and 90% in a developing world context (Quigley and Broman, 2006).  
 
2.1.6 Clinical presentation of glaucoma 
One of the greatest challenges of the disease, apart from being a potentially blinding condition (Kanski, 
2007), is its asymptomatic nature (Leite et al. 2011). The diagnosis of glaucoma is made by highly 
trained professionals performing a multitude of necessary tests, however, when resources are limited, 
the difficulty of this task is exacerbated (Leite et al. 2011). Retinal ganglion cell death and optic nerve 
fibre loss in glaucoma result in the characteristic “cupping” appearance occurring at the optic nerve 
head and retinal nerve fibre layer (Weinreb et al. 2014).  In addition, the lamina cribrosa and its adjacent 
tissues, in particular, are strained by increased levels of IOP, although it is known that individuals with 
normal levels of IOP can also present with GON (Weinreb et al. 2014). According to the Journal of 
American Medical Association (JAMA) Rational Clinical Examination systematic review of POAG 
diagnosis, an increased cup-to-disc ratio (CDR), CDR asymmetry, disc haemorrhage, or elevated IOP, 




Whilst most patients with the disease have nearly “good” visual acuity, patients with glaucoma often 
complain of having “poor vision”, however, Snellen visual acuity usually only deteriorates when the 
glaucoma has advanced (Hawkins et al., 2003). Apart from light sensitivity, (probably the greatest 
symptom) there are other aspects which are involved when a patient has this condition- poor motion 
perception, decreased discrimination of high spatial frequencies and abnormal colour vision (Crabb et 
al., 2013).  In 1912, Kollner described colour vision loss due to ocular disease- Kollner’s rule- which 
states that those patients with retinal disease will develop blue-yellow colour vision loss, whilst those 
with optic nerve disease will develop red-green colour vision loss, with one of the exceptions being 
glaucoma- presenting with predominantly tritan colour vision deficiency (Pacheco-Cutillas et al. 1999).   
 
Visual field loss has been the most documented functional deficit occurring with glaucoma and has 
been frequently misrepresented as a black tunnel or patches obscuring parts of the patient’s field of 
view, however Crabb et al. (2013) found that patients with glaucoma perceive their field of view as a 
combination of perceiving blur and missing areas.  Scotomas in a pre-chiasmal, nerve fibre bundle-type 
distribution occur as a functional deficit, matching observed changes at the ONH (Casson et al., 2012). 
Paracentral scotomas and a reduction of sensitivity in the arcuate regions are common visual field 
defects in early glaucomatous optic neuropathy (Pacheco-Cutillas et al. 1999). It was also found in 
patients with glaucoma, with visual acuity  of 20/40 or better, there is a significant correlation between 
a reduction in contrast sensitivity and visual field loss- with the disease affecting contrast sensitivity 
more than Snellen acuity (Hawkins et al., 2003).  
 
2.2 Glaucoma in developing countries 
In developing countries, vision impairment remains a serious global eye health issue, with Africa 
accounting for 16.6% of the current global distribution of blindness (Jaggernath et al., 2014). The 
majority of preventable ocular problems (cataracts, trachoma, conjunctivitis, etc.) which can cause 
vision impairment and lead to blindness in developing countries are linked closely with poverty, mainly 
through lack of sanitation, poor or inadequate water supply, malnutrition and the lack of education 
(Jaggernath et al., 2014).  
 
Glaucoma generally goes undiagnosed in developing countries (Quigley, 1996) because of lack of 
awareness of the disease and its effects (Rait, 1996) and has been included as a third major cause of 
blindness (Jaggernath et al., 2014).  In developed countries, less than 50% of those affected with 
glaucoma are aware of their condition (VeSathyamangalam et al., 2009), however, the diagnosis of 
glaucoma occurs at a much earlier stage than in developing countries due to the increased awareness of 
the condition (Attebo and Mitchell, 2007). The costs of standard methods for screening, including 
computerised perimetry, are not affordable, lengthy (Govender et al., 2015) and are relatively 
inaccessible in most developing countries (Ong et al., 2014). 
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In addition, the lack of financial and human resources required for basic eye-care services are not 
available, with the number of ophthalmologists available in developing countries estimated to be at one 
per 500 000 in Africa and one per 200 000 in Asia (Thomas, 2012).  In South Africa, the ratio of 
optometrists to the population is approximately 1:17600 (Naidoo, 2007), however most are confined to 
the cities and serve only those with medical insurance. Reliance on opportunistic case finding by 
practitioners rather than comprehensive community based screening will, therefore, result in patients 
developing substantial visual field loss before glaucoma is actually diagnosed (Thylefors et al., 1995). 
 
2.2.1 Barriers to accessing eye care services in South Africa 
The total population of South Africa is approximately 54 million, with males making up 51.3%, and 
females 48.7% (Statistics South Africa, 2014).  Majority of this population is made up of individuals of 
African origin- 79.2%, followed by 9.6% Caucasians; 8.9% Mixed race; 2.5% Indians/Asians and 0.5% 
of other race groups (Statistics South Africa, 2014). Figure 2.2 below graphically depicts the 
distribution of eye health care in South Africa. Eighty percent of the population rely on the services of 
the public sector, whilst the remaining 20% are served by the private sector – see Figure 2.2 (Keeton, 
2010).  
 
Figure 2.2. Distribution of eye health care services between the public and private sector 
One of the nine provinces of South Africa, KwaZulu Natal (KZN), has the second-largest population in 
the country, estimated at just over 9.5million (Statistics South Africa, 2014).  Making up the population 
are people of African, Indian, Caucasian and Mixed race origin.  Individuals of African origin make up 
8.1 million (83.5%) and those of Indian origin  (804 839) 8.2% of the total population in KZN, with 
Mixed race and Caucasians making up 2.5% and 5.7% respectively (Jacobs et al. 2009).  
Despite suggestions that around 80% of vision impairment is reversible and treatable, it still remains a 
serious global health issue with over 285 million people having vision impairment, and glaucoma being 
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the third major cause of blindness, after cataract and uncorrected refractive error (Jaggernath et al., 
2014). It has also been suggested that poverty and eye health often have a direct and indirect link, with 
poverty being closely related to education levels (Jaggernath et al., 2014). Just over half (50.9%) of the 
world’s poor are located in Africa (Jaggernath et al., 2014) and Statistics South Africa reported the 
poverty level in KZN was recorded at 69.1% (Statistics South Africa, 2011). 
 
In 2006 it was noted that 76.7% of households in KZN, South Africa, headed by those without formal 
education, were living in poverty (Statistics South Africa, 2011). In the public sector of the province, 
there are 38 optometrists currently employed (Naidoo et al. 2013) and only about 25% of 
ophthalmologists in the province serve the public sector (Dhlomo, 2013).  
 
In 2003, WHO reported more than 60% of South African health care institutions found it difficult to fill 
existing posts and this critical shortage of trained personnel plays a fundamental role in the 
implementation of health services at district level (Kautzky and Tollman, 2008). Further, the public 
sector provides to an estimated 35 million people, and receives only about 38% of the national health 
expenditure, in comparison to the 62% provided to approximately 7 million people of the private sector 
(Kautzky and Tollman, 2008).  
Research has shown that timely intervention can prevent blindness (Kayange et al., 2014) and therefore 
screening must be efficient and effective enough to detect patients with glaucomatous changes. 
 
2.2.2 Challenges faced in accessing health care in South Africa 
In a developing country, such as South Africa, the accessibility and availability of health care to the 
population should not be an unaffordable burden on individuals. Factors such as: race, socio-economic 
status, insurance status and urban-rural location, influence the access to care. These factors should 




Figure 2.3 Health access framework 
2.2.2.1 Accessibility, availability, and affordability of eye care services  
The challenge amongst individuals residing in rural and remote areas, is the lower socio-economic 
status which contributes significantly to poverty. These individuals are faced with an inadequate supply 
of eye care services due to the limited or non- availability, accessibility, and affordability of these 
services, as depicted in Figure 2.3 above. These three key factors which majorly influence access to 
health care is collectively termed the “Health access framework’’. In addition to these, cultural beliefs 
can also influence the utilisation of eye care services, where they are available (Ntsoane et al., 2012). 
In comparison to other countries in Africa, South Africa has more eye care practitioners available, 
however, the distribution of these personnel is poor and has impacted on the inaccessibility and 
unaffordability of services (Naidoo et al., 2003). Despite South Africa’s peaceful transition into a 
democracy since 20 years ago, there still remains a considerable burden with regards to the health of all 
its citizens, which include persistent social disparities and limited human resources (Mayosi and 
Benatar, 2014). In addition, the reduction of the overall burden of visual impairment and blindness, 
globally, can be closely associated with the education and awareness of the utilisation of eye care 
services (Ntsoane et al., 2012). 
 
2.2.2.2. Age influence  
Whilst research reports that older individuals are more susceptible to ocular diseases and are more likely 
to seek eye care services. Ntsoane et al., (2012), however, found  older individuals of Limpopo, South 
















It has been reported that in Africa, and globally, women are 1.4 times more likely than men to be blind 
(Mganga et al., 2011). Approximately two-thirds of the global burden of blindness is bore by women, 
the bulk of which is attributed to cataract (Lewallen and Courtright, 2002). It was noted that females do 
not receive the same rate of cataract surgery as males. According to a study, of the thirteen South African 
males blind by cataract, all thirteen had undergone cataract surgery intervention, whilst only less than 
half (20) of the 44 cataract blind South African females underwent cataract surgery (Lewallen and 
Courtright, 2002). In Africa, the prevalence of cataract blindness could be reduced as much as 12% if 
women received the same frequency of cataract surgery as men (Mganga et al., 2011). Socioeconomic 
factors such as socioeconomic status, marital status, literacy and gender-defined roles have been thought 
to influence the gender-based gap in seeking eye care and other health care services  (Lewallen and 
Courtright, 2002). Another suggested factor is the increased longevity in females as compared to males, 
making age-related ocular conditions (such as age-related macular degeneration and glaucoma) more 
rife amongst females (Abou-Gareeb et al., 2001). 
 
2.3 Glaucoma screening 
Screening tests are used when the gross impact of disease on the visual field is required as compared to 
a detailed one (Elliott, 2013). The present methods for glaucoma screening are expensive and are a 
barrier to identifying people at high risk for glaucomatous disease compared to other ocular diseases 
(Quigley, 1996). Apart from the cost, most of the current methods of screening require a significant 
amount of testing time (Johnson and Samuels, 1997) or sufficient expertise (e.g. for optic nerve 
examination). If glaucoma is left undiagnosed, treatment cannot be initiated and therefore many 
activities of daily living are affected as the disease progresses, including reading and writing, mobility 
and discrimination of colours (Taylor & Keeffe 2001); (Rong-jiang et al., 2011). In addition, lack of 
treatment can lead to blindness with its consequent health and socio-economic effects (World Health 
Organisation, 2006).   
 
2.3.1. Visual field perimetry and developments in glaucoma detection tests 
Visual field perimetry is vital in detecting the functional loss that accompanies glaucoma (Nouri-
Mahdavi, 2014) as well as measuring the severity and progression of disease (Peters et al. 2015).  These 
tests are subjective in nature and require the patient to understand the testing instruction, fully cooperate, 
and complete the entire test in order to provide accurate and reliable results (Alencar and Medeiros, 
2011). Visual field tests can be static, kinetic, and manual or automated (Dersu et al., 2006). An essential 
component for accurate diagnosis and implementation of appropriate management regimens is the 
reliability and repeatability of the visual field test (Newkirk et al., 2006). Factors influencing the 
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accuracy of visual field testing include refractive error, pupil size, ocular structural abnormalities and 
intraocular stray light.  Patient profile and co-operation, defective instruments, the operator’s technical 
skill, as well as the testing environment were also found to be contributing factors (Nussdorf and 
Alastair, 2003).  
 
2.3.1.1 Non-Automated visual field tests  
2.3.1.1 (a) Confrontation 
This is a screening method of visual field testing that has the potential to detect gross visual field defects 
in eye diseases, and is useful in picking up visual field loss in advanced glaucoma (Broadway, 2012).  
There are many variants of confrontation testing, which involves the comparison of the examiner’s 
visual field with that of the patient’s (Elliott, 2013). Confrontation testing is used to screen many 
abnormalities therefore one cannot  definitively diagnose glaucoma based on the results (Pandit et al. 
2001). Confrontation tests, when performed in combination, rather than individually  were  found to be 
more sensitive in detecting visual field loss (Kerr et al., 2010). 
 
2.3.1.1 (b) Tangent Screen (Campimetry or Scotometry) 
The Tangent screen allows the patient’s central and paracentral 30-degree visual field to be mapped out 
and  can detect up to 90% of all visual defects in the testing area (Broadway, 2012; Bhalla et al., 2016). 
It is a relatively simple screening method to use and is more sensitive than the confrontation technique, 
however, is not as sensitive as automated perimetry in detecting early defects (Bhalla et al., 2016). 
As the examiner, a few precautions need to be taken, such as: careful monitoring of patient fixation and 
maintaining a proper testing distance, adequate illumination (Broadway, 2012) and instructions to 
patient, proper movement of target and mapping from blind to visible area (Bhalla et al., 2016). 
 
2.3.1.2 Automated visual field tests 
2.3.1.2 (a) Standard Automated Perimetry (SAP) 
Standard automated perimetry (SAP) is considered to be the gold standard methodology in the 
assessment of visual fields (Patyal et al., 2014).  The Humphreys Visual Field Analyser (HVFA) is a 
standard automated perimeter (Alencar and Medeiros, 2011).  However, SAP instruments are expensive 
and not portable, with longer test duration; thus, it is not the instrument of choice for screening visual 
fields in primary eye care settings (Bergin, 2011). Research has shown that up to 50% of retinal ganglion 
cells are lost before a visual field defect can be detected with SAP (Ong et al., 2014).  
18 
 
Although recent developments have seen the advent of more sophisticated psychophysical visual 
function tests, visual field instruments remain expensive and relatively inaccessible in rural or 
underdeveloped areas (Ong et al., 2014).  
 
2.3.1.2 (b) Humphreys Visual Field Analyser (HVFA) 
The HVFA is regarded as the gold standard among standard automated perimeters (Choplin et al. 1998). 
Two thresholding strategies are offered using the HVFA, namely the 24º strategy (24-2) which tests 54 
points, and the 30º (30-1) strategy which tests 76 points (Kanski, 2007).  HFVA results are normally 
represented as a grey scale image and are further presented via analysis software (Statpac) provided by 
the instrument (Artes, 2012). It computes maps of the total deviation, pattern deviation and global 
indices such as mean deviation (Kanski, 2007). The total deviation map presents decibel deviation from 
age-corrected normal threshold sensitivity (Artes, 2012).  Even though the grey scale map seems the 
easiest to evaluate, it is less reliable compared with the total and pattern deviation probability plots 
(which prove very useful when distinguishing the effects of cataract from glaucomatous damage on the 
visual fields) (Alencar and Medeiros, 2011).   
 
The HVFA uses two programmes for glaucoma screening, the SITA Standard (SS)  and SITA Fast (SF) 
(Pierre-filho et al., 2006). The Swedish Interactive Threshold Algorithms (SITA) is incorporated into 
the HVFA, which also includes three reliability indices: false positives, false negatives and fixation 
losses (Newkirk et al., 2006).  Those patients whose fixation losses exceed 20% or whose false positive 
or false negative errors exceed 33% are not considered reliable (Newkirk et al., 2006). The full threshold 
strategy has been the most utilised practice for monitoring glaucoma, however, recent advances have 
proven many other test strategies, including SITA, that reduces test duration and patient fatigue 
(Newkirk et al., 2006). Patients may need to take a break between testing each eye due to fatigue and 
this can result in inaccuracies in results (Reddy, 2006). The Glaucoma Hemifield Test (GHT) provides 
a useful summary measure of the visual field which may be classified as outside or within normal limits, 
borderline, or as having a general reduction in retinal sensitivity, providing statistical evidence about a 
visual field defect (Burr et al., 2007). 
 
2.3.1.2 (c) Frequency Doubling Perimetry (FDP) 
The frequency doubling effect is a phenomenon that occurs when a low spatial-frequency (<4cyc/deg) 
grating that undergoes high temporal-frequency (>15Hz) counter-phase flicker appears as a shimmering 
grey pattern with double the original spatial frequency (Chauhan and Johnson, 2000).  
Frequency doubling technology (FDT) perimetry determines the contrast sensitivity for detecting the 
frequency doubling stimulus (Alencar and Medeiros, 2011). Frequency Doubling Perimetry has a high 
sensitivity and specificity in detecting glaucomatous visual field loss, as well as a significantly shorter 
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test duration as compared to conventional perimetry (Chauhan and Johnson, 2000). It is also portable 
and considerably easier to use for the patient and the examiner, and seems to be promising in the field 
of early glaucoma diagnosis (Alencar and Medeiros, 2011). Images of the patient set-up and the FDT 
result sheet can be seen below in Figure 2.4(a) and Figure 2.4(b). 
 
Figure 2.4(a) Frequncy Doubling Technology (FDT) result sheet 
https://www.researchgate.net/figure/Frequency-Doubling-Technology-FDT-Visual-Field-Tests-showed-normal-VF-OD-
and-a-few_fig7_49616993                             
 
Figure 2.4(b) FDT patient set-up 
http://oogziekenhuis.me/Frequency_Doubling_Perimetry/Frequency_Doubling_Perimetry.html 
2.3.1.2 (d) Rarebit perimetry (RBP)/(Microdot perimetry)  
Rarebit perimetry (RBP) is another perimetric method that comprises very small stimuli (individual 
dots) against a dark background, presented on a regular computer liquid crystal display (LCD) monitor 
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(Brusini et al., 2005).  Microdots are used to evaluate the density of coverage within the central 30º of 
the visual field, with deeper defects having a larger density of micro-holes (Alencar and Medeiros, 
2011). Although the use of RBP on glaucomatous patients has yet to be reported in the literature, it has 
proven promising in detecting the early visual field damages in patients with neurological disorders 
(Brusini et al., 2005). 
 
2.3.1.2 (e) Microperimetry 
Microperimetry, also known as fundus perimetry (Lima et al., 2010),  assesses visual field sensitivity 
between (0 and 34 decibels) by directly projecting a target light onto the retina, as can be seen in Figure 
2.4(c) below (unlike onto a screen like with the gold standard HVFA) (Matsuura et al., 2018). Tracking 
of the retinal location is automatic and target location is then aligned accordingly. Measurements are 
carried out similar to the HVFA, and the MP-3 Microperimeter uses a 4-2 full-threshold staircase 
strategy, assessing 68 points on the 10-2 test grid. Reliability indices of the Microperimeter is the same 
as compared to the HVFA and upon validating this instrument whilst evaluating glaucoma patients, the 
MP-3 Microperimeter was found to have a similar test-retest reproducibility relative to the HVFA, but 
an improved structure-function relationship with the Ganglion Cell Complex (GCC) thickness. The MP-
3 Microperimeter did, however, have a longer mean test duration of 10 minutes and 29 seconds (10m29s 
± 2m55s) as compared to the HVFA (mean test time of 7m06s ± 0m49s) (Matsuura et al., 2018). Lima 
et al. (2010) concluded that Microperimetry detected a reduction in retinal sensitivity in OCT 
structurally damaged areas with normal SAP results, and suggests subtle paracentral functional deficits 
may be present in a higher number of glaucomatous eyes than what is generally believed. 
 




2.3.1.2 (f) Moorfield’s Motion Displacement Test (MMDT) 
Professor Fitzke, from the Institute of Ophthalmology at University College London (UCL), developed 
the original Motion Displacement Test (MDT) in the 1980’s (Moorfield’s Eye Hospital: NHS 
Foundation Trust, 2008).  It comprised of a single line stimulus presented just above the blind spot on 
a computer and was found to be a detector of glaucomatous visual field loss (Moorfield’s Eye Hospital: 
NHS Foundation Trust, 2008).  Evidence of elevated motion displacement threshold was shown in areas 
of the visual field not usually affected when assessed by SAP (Westcott et al. 1998) and the MDT 
proved to be resistant to the effect of media opacity (Loughman et al., 2013).  These properties provided 
the rationale for the development of the test to take on a multi-location format and in 1999 the 
Moorfields Motion Displacement Test (MMDT) developed by the Glaucoma Research Unit at 
Moorfields in combination with the Institute of Ophthalmology, UCL, was introduced (Moorfield’s Eye 
Hospital: NHS Foundation Trust, 2008).
 
Figure 2.4(d) Moorfields Motion Displacement Test (MMDT) with patient set-up 
   
 





The MMDT is a multi-location test, presenting vertical line stimuli in 32 test locations (Figure 2.4(e) ) 
on a computer screen; each scaled by estimate of retinal ganglion cell density and selected using the 
Garway-Heath anatomical map (Loughman et al., 2013). The MMDT aims to determine the smallest 
perceptible positional displacement, with the displacement giving rise to the sensation of movement 
(Verdon-Roe et al., 2006). However, its accuracy in comparison to the HVFA has not yet been 
established.  Therefore, this study set out to compare the visual field defects, if any, obtained by the 
Moorfields MMDT to that obtained with the HVFA in diagnosed glaucoma subjects.   
 
Research has found that there was an indication of good topographical correspondence of the MMDT 
with Standard Automated Perimetry, showing 70% point-wise agreement of the 32 matched locations.  
Ong et al. (2014) concluded that the supra-threshold MMDT showed good diagnostic performance for 
diagnosing glaucoma, when glaucoma was defined by structural criteria. It was also found that this 
perimetric method for the detection of clinically and structurally defined glaucoma produced excellent 
sensitivity and specificity values of more than 85%, which are clinically significant (Ong et al., 2014). 
 
Currently, the Moorfields MMDT offers 2 strategies (Bergin, 2011): 
1. The Enhanced Supra-Threshold Strategy (ESTA) which takes 90-120 seconds per eye and is 
designed for rapid case finding in the community (Bergin, 2011) 
2. The Weighted Binary Search Threshold Strategy (WEBS) which takes approximately 9.4s per 






Figure 2.5 Location of MMDT locations on the retina. (Verdon-Roe et al., 2006) 
http://www.iovs.org/content/47/11/4847.short 
 
Figure 2.6 Schematic structure-function map according to (Garway-Heath et al., 2000) Visual test 
points/sectors of the visual field can be related to sectors of the ONH. 
http://openi.nlm.nih.gov/detailedresult.php?img=3585161_pone.0057663.g004&req=4 
 
The first plot on the MMDT result page is the 'pass/fail' plot which is determined by the displacements 
seen or missed at a specific location, as well as performance at anatomically related locations. The 
second plot is the 'probability' plot which is determined by the spatial filter of the ESTA. The values in 
this plot estimate the 'probability of true damage' (PTD) which is calculated according to the relationship 
between each field location and the number of unseen responses. A higher PTD indicates a higher 
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probability that the location is damaged- a value of more than 3 is regarded as a fail (Loughman et al., 
2013). The last plot is the 'greyscale' plot which applies the Garway-Heath anatomical map to relate the 
field defect to the optic nerve head. Each letter on the field corresponds to the anatomically related 
sector of the optic nerve head (Garway-Heath et al., 2000).  Global PTD represents the sum of the PTD 
for each location. This figure is then divided by 100, recorded to 2 decimal places. Again, the higher 
the value of PTD, the higher the probability of 'true damage' (Loughman et al., 2013). 
 
A challenge with making comparisons between the MMDT and Standard Automated Perimetry (SAP) 
is that different measurement scales are applied to different psychophysical stimuli (Moorfield’s Eye 
Hospital: NHS Foundation Trust, 2008). Currently, the NHIS Biomedical Research Centre for 
Ophthalmology at the Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of 
Ophthalmology are developing a reference scale for improved comparison between the MMDT and 





2.4 Factors influencing the accuracy of visual field testing  
The factors known to influence the accuracy of visual field testing include:  
2.4.1 Refractive error 
Refractive error has an effect on the visual field test results obtained with some instruments since it 
decreases stimulus clarity and therefore the determination of the subjects’ refractive error and near 
addition is crucial when conducting the HVFA (Nussdorf and Alastair, 2003). Research has found that 
if the patient’s prescription is incorrect, increased variability of visual fields and refractive scotomas 
can result (Johnson, 1996; Rowe and Meigen, 2007). A significant decrease in central sensitivity is seen 
in uncorrected subjects (Corallo et al. 1997). Myopes with normal tension glaucoma and primary open 
angle glaucoma were found to have a decrease in sensitivity in the lower centro-cecal area of the visual 
field (Johnson, 1996).  Corallo et al. (1997) found defects in high myopes ( >7.00 DS). The standard 
procedure is that most perimetry is performed with a stimulus at approximately reading distance, so a 
near correction should be used for presbyopic patients (Bergin, 2011).  When using the MMDT, testing 
patients with uncorrected refractive error has little impact on the ability of the MMDT to discriminate 
between healthy and glaucomatous eyes (Bergin, 2011). This is important as the MMDT is envisaged 
to be beneficial as a screening test in the community, where there may be a lack of time to assess the 
need for refractive correction (Loughman et al., 2013). 
 
2.4.2 Pupil size 
It is important to maintain a constant pupil size by maintaining standardised illumination conditions 
during and between tests as it influences test results (Nussdorf and Alastair, 2003). Miosis decreases 
sensitivity in the peripheral field and increases variability in the central field in both normal and 
glaucomatous eyes (Mendivil, 1997).  
 
2.4.3 Ocular structural abnormalities 
Structural abnormalities of the eyelids or orbits can bring about variations in visual field test results and 
abnormalities such as ptosis, dermatochalasis, prominent eyelashes, and deeply set eyes can cause a 
decrease in the superior visual field (Alastair and Denniston, 2009). The development of media 
opacities, such as cataract, can also affect the results (Chauhan and Garway-Heath, 2008), however, the 
Moorfields MMDT is robust to optical blur and cataract (Moorfield’s Eye Hospital: NHS Foundation 




2.4.4 Intraocular stray light 
Research has indicated that moderate to large increases in intraocular stray light (IOS) has significantly 
affected perimetry thresholds in tests like the Standard Automated Perimetry (SAP), Frequency-
doubling technology (FDT) perimetry and Flicker-defined Form (FDF) perimetric tests (Bergin et al., 
2011). However, the Moorfields MMDT has remained largely unaffected by the same range of stray 
light levels (Bergin et al., 2011). Furthermore, it was found that luminance reduction and light scattering 
have marked effects on frequency doubling and conventional white-on-white perimetry, but little effect 
on motion displacement perimetry (Membrey et al. 1998). 
 
2.4.5 Other factors 
A variety of other factors including the patient profile and co-operation, defective instruments, the 
operator’s technical skill, as well as the testing environment can also influence the accuracy of visual 
field testing (Nussdorf and Alastair, 2003). Additional factors which can influence test outcomes 
include cognition, attention, higher order functions, practice, learning and fatigue, especially after 5-7 
minutes of testing (Infeld, 1998). Since the original MMDT was found to be too long for screening 
purposes i.e. 5-7 minutes per eye, the development team collaborated with City University since 2006 
to develop methods with the aim of reducing the test duration (Moorfield’s Eye Hospital: NHS 
Foundation Trust, 2008).  Other factors include the stimulus size, diabetes, alcohol (Wild and Betts, 
1990) and drug abuse which causes depression of the central nervous system (Nussdorf and Alastair, 
2003). 
 
2.4.5.1 Importance of improving test duration during visual field assessment 
It is essential that the patient’s responses are monitored during testing as these impact on the reliability 
of test results. Therefore, by reducing test duration, more reliable and repeatable results should be 
obtained due to a less fatigued patient (Newkirk et al., 2006). Despite advances in automated perimetry, 
visual field testing (although non-invasive) still remains subjective in nature as it depends largely on 
the patient’s responses (Rudnicka and Owen, 2007). Bergin et al.(2011) reported of three screening 
perimetric devices, the Frequency Doubling Technology C-20 (FDT C-20) was the fastest (63 sec), 
followed by the MMDT ESTA (102 sec) and lastly Standard Automated Perimetry (SAP) (171 sec), 
when testing glaucomatous subjects. Part of this difference in test duration could be attributed to the 
smaller number of test locations included in the FDT (17 test points) and MMDT (32 test points) as 
compared to the HVFA (54 test points) (Bergin, 2011). This is potentially highly advantageous for 
screening purposes as a means to optimise use in community-based settings, allowing for improved 




2.4.5.2 Anxiety levels and glaucoma  
The patient’s response with regard to their motivation and anxiety also contribute to the testing results 
and is one of the most important factors which often gets ignored by the practitioner (Infeld, 1998). It 
has been reported that up to 63% of referrals are false positives, therefore screening is essential as over-
referrals generally cause an unnecessary anxiety and inconvenience to the patient, as well as excess 
burden on health care resources (Burr et al., 2007). A study conducted by Chan et al. assessing 
psychosocial functioning with use of the Glau-QoL-36 questionnaire, found an adverse effect of early 
stage glaucoma on anxiety, self-image and confidence in health care. A further increase in anxiety levels 
as visual acuity and self-image deteriorates was also noted (2015). The study concluded that those 
patients with glaucoma had 63% higher anxiety, 71 % lower self-image, 38% lower psychological well-
being and 32% lowered  confidence in health care as compared to the control group (Chan et al., 2015). 
2.4.5.3 Familiarity with use of a mouse  
It was reported, during a study on the impact of computer knowledge on the reliability of results 
obtained from the MMDT, that the majority of subjects were excluded because of their inability to 
effectively use a computer mouse during extended testing periods. This consequently resulted in a high 
false positive rate (Loughman et al., 2013). In another form of screening visual fields, RareBit Perimetry 
(RBP) was found to be a faster and easier form of screening as compared to SAP, however, the only 
challenge occurred in the elderly age group who were unfamiliar with the use of a computer mouse 
(Brusini et al., 2005). Besides the unfamiliarity with the use of a computer mouse, it is also vital to 
acknowledge the onset of glaucoma which predominantly occurs in the elderly, many of whom have 
dexterity issues, amongst various other ageing processes. Generally, reflexes slowdown in the elderly, 
along with hearing loss- all of which contribute to the understanding and performance of the test 
(Voelcker-Rehage, 2008). The above reasons indicate the need for customised buttons as a method of 
selection when using a computer-based visual field test (Loughman et al., 2013). Due to the above-
mentioned factors, it was decided that the subjects’ experience using a mouse versus button be 
evaluated. 
 
2.5 Advancements in visual field testing 
 
2.5.1 Head mounted perimeter “imo” 
The head mounted perimeter ‘imo’ (CREWT Medical Systems, Inc., Tokyo, Japan) was released in 
2015 and consists of a main perimeter unit, user control tablet and patient response button, with the left 
and right optical system completely separated and can be performed without a dark room- allowing for 
mass screening (Matsumoto et al., 2016; Yamao et al., 2017). This device can display the same test 
target as the HVFA using full High Definition transmissive LCD and high intensity LED backlights 
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(Matsumoto et al., 2016; Yamao et al., 2017). The examiner controls the user tablet via Wi-Fi and the 
patient’s response button is connected via Bluetooth which receives all patient responses (Matsumoto 
et al., 2016). The wide-angle lens system measures the visual field within 35 degrees from the fovea 
(Goseki et al. 2016). It is performed at a viewing distance set at 1m and can be performed on patients 
with an uncorrected refractive error of -9.00DS to +3.00DS (Matsumoto et al., 2016). An additional 
special feature is the binocular random single eye test (Matsumoto et al., 2016; Yamao et al., 2017). 
Importantly, the imo test patterns are compatible with those for the HFA 30–2, 24–2, 10–2 and 24+ test 
programs with additional test points in the central 10°VF of the 24–2 program (Matsumoto et al., 2016). 
It is light and compact, thereby allowing for the test to be performed in almost any location (Yamao et 
al., 2017). 
2.5.2 Melbourne Rapid Field (MRF) 
The Melbourne Rapid Field (MRF), a novel visual field test, is an iPad based tangent perimeter, able to 
perform fast thresholding at several locations within 30 degrees of fixation (Kong et al., 2016; 
Nesaratnam et al., 2017). Its portability and shorter test duration (approximately 4.5 minutes per eye) 
is an advantage over conventional standard  automated perimetry as it allows for the test to be performed 
on patients who are bed-bound or in situations where visual field testing equipment is inaccessible, such 
as in developing countries and rural areas (Vingrys et al., 2016; Nesaratnam et al., 2017). The test is 
performed under monocular conditions and the patient is asked to fixate a target on the iPad tablet at a 
distance of 33cm and is required to tap on the screen with their finger every time a stimulus is seen 
(Kong et al., 2016; Vingrys et al., 2016). As with conventional perimetry, reliability indices include 
fixation losses, false positive and false negative errors (Nesaratnam et al., 2017). 
 
From the literature, it is evident that medical technology has advanced to optimise patient diagnosis and 
management. Over the decades, there have been many improvements on visual field instruments in 
detecting various ocular diseases, most specifically, glaucoma. Whilst vision impairment remains a 
serious issue in developing countries, there are still many barriers in accessing eye health care. Some 
of the reasons include limited affordable and adaptable solutions enabling remote access, lack of 
resources, socio-economic status and level of education. It is therefore essential that the improvements 
in technology consider the portability, affordability and accessibility of the instruments to allow for 




CHAPTER 3: Research methodology and design 
 
The following chapter highlights and justifies the scientific basis of the study and will explain in detail 
the processes involved to conduct the study. 
 
3.1 Introduction 
This chapter explores the research methodology and design of the study, the processes and methods 
used to achieve the study objectives. 
 
3.2 Study design: This was an observational, analytical study (involving comparative and quantitative 
methods). 
 
3.3 Setting: The study was conducted at McCord’s Provincial Eye Hospital and Prince Mshiyeni 
Memorial Hospital, district hospitals in KwaZulu Natal, South Africa. McCord Hospital was established 
in 1909 by Dr James McCord, who was sent to South Africa by the American Board Missions. The 
iconic hospital was one of the first institutions in the country to implement training programmes in 1914 
for black nurses. During the apartheid days, unsuccessful attempts were made to shut the doors to 
McCord Hospital. After its closure in 2012, McCord Hospital was taken over in February 2014 and the 
doors were once again opened to serve members of the community. It now functions primarily as a 
provincial eye hospital (2017). 
 
 
3.4 Participants: Participants with glaucomatous (case) and non-glaucomatous (control) eyes were 
invited to participate in the study. Permission to access patient files was obtained from hospital 
management to extract demographic and clinical data for potential participants (Appendix 8 and 9). A 
chart review revealed participants diagnosed with glaucoma who were scheduled to attendthe eye clinic 
to form the case group. Those participants booked for refraction at Prince Mshiyeni Memorial Hospital 
(PMMH) were recruited as controls.   
 
3.5 Sampling: A purposive sampling strategy was used to select the test subjects sample from the 
population of participants diagnosed with glaucoma, at McCord Provincial Eye Hospital, a district 
hospital in KwaZulu Natal, South Africa. All those subjects booked for refraction at PMMH without 
ocular pathology were selected for the control group, after careful review of their chart to ensure 
inclusion criteria were met. Data was collected from Monday to Friday between 08h00 and 14h00.  
 
3.5.1 Sample size:  A qualified statistician from the African Vision Research Institute (AVRI) was 
consulted to determine the sample size. When assessing the diagnostic accuracy of a new instrument 
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relative to the gold standard, it is important to assess the sensitivity and specificity of the instrument, as 
well as the positive and negative likelihood ratios in order to further validate the performance of the 
new instrument. After estimating the confidence intervals, the margin of error was found to be 12.2% 
for sensitivity (73%) and 8.2% for specificity (90%) (Baez et al., 1995). Two samples were established 
separately since sensitivity and specificity are calculated from the true-positive and the true-negative, 
respectively. These values are usually different since there is a trade-off between sensitivity and 
specificity. Power analysis was used to establish narrower confidence intervals for the sensitivity and 
specificity estimates.  
 
Calculation: 
A three-step method was used to approximate the sample size n* with 90 % power to estimate p with a 
margin of error no more than M. Step 1 calculates a preliminary estimate n based on p●, the estimated 
sensitivity or specificity and M. Step 2 gives ‘power’ to the sample size estimate by calculating p*, or 
the 90 % lower bound around p● given n. Step 3 calculates n* using the same equation as Step 1, but 
substituting p* for p●  




 Step 2: 
  ?̇?∗ =  ?̂? - 1.282 √





 𝒏∗ =  (
𝟏.𝟗𝟔
𝑴
)². 𝒑∗ (𝟏 − 𝒑∗) 




Where n= sample size; M= margin of error; p●= estimate of sensitivity or specificity; p*= lower bound 
of 90% Confidence Interval (CI); n*= approximate number of samples needed for 90% power 
Using the estimates above and the desired margin of error of less than or equal to 5%, the minimum 
sample size for the true-positive was calculated to be 177 and the minimum sample size for the true 
negative calculated to be 324 (Hess et al., 2012). 
  
 M P  
INPUT 5 73 Values 
in % 
 0.05 0.73 Values 
in decimal 
n 51  
 Decimal Percentage (%) 
P- 0.608153153 60.8153153 
P+ 0.851846847 85.1846847 
ME= 12.184684751  
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3.5.2 Sampling technique 
Inclusion criteria: 
The following subjects were eligible for inclusion in the study: 
• Subjects diagnosed with glaucoma 
• Subjects of all race groups 
• Subjects of both genders 
• Adult subjects (aged 40 years and older) 
•  “control” subjects included all those participants without any history of ocular pathology 




The following subjects were excluded from the study: 
• Subjects diagnosed with ocular pathology other than glaucoma 
• Subjects with corrected visual acuity worse than 6/12 (to rule out other pathology or sources of 
variability 
• Subjects with refractive error greater than +4.50DS and -6.00DS (due to the custom-specific 
sizing of the four central stimuli, which is resistant to optical defocus within the range of 
+4.50DS to -6.00DS) (Loughman et al., 2013) 
 
3.6 Data collection methods: 
3.6.1 Preliminary testing: 
For the case group, McCord Provincial Eye Hospital was visited on the days allocated to glaucoma 
participants, whilst for the control group, participants booked for refraction at Prince Mshiyeni 
Memorial Hospital were approached regarding participation. Access to patient files was obtained from 
the hospital in order to extract demographic and clinical data. Each participant was provided with an 
information document (Appendices 1 and 2) and consent form (Appendices 3 and 4) (in their home 
language, which was then signed and attached to their questionnaire. The questionnaire (see appendix 
5- data collection form) was provided to each participant which had to be answered prior to testing as 
well as after. The questionnaire was divided into two sections- the first pertaining to ocular, medical 
and family history, whilst the latter dealt with the factors associated with visual field testing. Prior to 
visual field testing, participants had undergone visual acuity testing, autorefraction, tonometry and 
ONH assessment. Optic nerve head assessment and tonometry were performed by a qualified 




3.6.2 Testing procedure: 
All subjects were tested in an isolated dark room, with minimal distractions from the surrounding 
hospital setting. Testing procedure commenced at 08h00am each day and concluded by 15:30. Most 
subjects were accompanied by a relative or friend, and were seated outside the testing room. The process 
started off by accessing patient files for the day and selecting the subjects based on the inclusion and 
exclusion criteria. The subjects were then approached by myself and the 3rd and 4th year optometry 
students to participate in the study. All those subjects who volunteered provided consent prior to visual 
field testing. Each subject was required to undergo a demonstration run for approximately one minute 
on both the HVFA and the MMDT in order to familiarise themselves with the testing procedure. Both 
eyes of the subjects were tested on each instrument and included in the data analysis. Subjects were 
required to answer a questionnaire, prior to and after visual field testing on both instruments to gain 
additional pertinent demographical, family, ocular and medical history, as well as subjective responses 
pertaining to the use and preference of the visual field instruments.  
 
The order of testing between subjects was randomised such that approximately half started with the 
MMDT and half with the HVFA. The sample size required for the study were 177 case subjects and 
324 control subjects. Due to the population at the two district hospitals selected, the total number of 
case subjects tested were 181, whilst the total number of control subjects tested were 328. Among the 
control subjects, 42 participants were monocular, whilst for the case group, only 12 participants were 
monocular. The total number of eyes tested for case and control subjects were 352 and 618, respectively.  
Reliable results obtained on the HVFA included: false positive rate of ≥20%, and a fixation loss value 
of ≤20%, whilst for the MMDT, the inclusion criteria for reliable data were: false positive value of ≤5% 
and a Global PTD of ≤3. Of the 352 eyes tested in the case group, reliable results were obtained for 94 
eyes, whilst of the 618 eyes tested in the control group, reliable results were obtained for 199 eyes. 
After considering all reliable data, the total number of participants in the study for the case group were 
sixty-two (62) and that of the control group were a hundred and forty-five (145). This totalled a sum of 
two hundred and seven subjects (or 293 eyes) which were included in the study.  The results for each 
instrument were masked from both examiners. A portion of subjects were selected at McCord’s 
Provincial Hospital for quality assurance to ensure reliability and validity. Once the subject had been 
tested using both instruments, they were then asked to answer a detailed questionnaire and were 
provided with a small token of appreciation for participating in the study. All subjects with glaucoma 
had been advised to have their immediate family members screened for glaucoma.  
 
For the control group, subjects were informed if any areas of concern were noted and were referred to 
the necessary hospital personnel for appropriate management. Participants were excluded from the 
analysis if their results displayed a false positive value of 5% and above on the MMDT, and on the 
HVFA, a false positive rate and fixation losses of more than 20%.   
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The MMDT is used in the assessment of visual fields and the 32-location program fits on a standard 
15-inch laptop screen (Loughman et al., 2013; Ong et al., 2014), performed at a test distance of 30cm 
(Ong et al., 2014).  The patient is required to place their head and chin on a purpose-built head and chin 
rest and the eye to be tested has to be directly aligned with the central white spot, with the patient 
maintaining fixation on this spot for the duration of testing (Ong et al., 2014). While maintaining 
fixation on the central white spot, the patient is required to click on the mouse every time a line on the 
screen is seen to move (Ong et al., 2014).  Each of the 32 line stimuli are scaled by estimation of retinal 
ganglion cell density and each location corresponds to a location on the Humphrey 24-2 program 
(Loughman et al., 2013), allowing point to point (sectoral) comparison between the 2 instruments 
(Moorfield’s Eye Hospital: NHS Foundation Trust, 2008).   
 
3.6.3 Testing with the Humphreys Visual Field Analyser (HVFA): 
The HVFA consists of a hemispherical bowl onto which a target can be projected at any location in the 
visual field (Kanski, 2007). Stimulus intensity is varied by altering luminance to determine the threshold 
level for each point tested in the visual field (Kanski, 2007). This is done by flashing random lights of 
different light intensities into the peripheral visual field while the patient is fixating at a source straight 
ahead. The patient is asked to then press the buzzer each time a light is perceived (Artes, 2012).  
 
3.6.4 Testing with the Moorfields Motion Displacement Test (MMDT) 
In contrast to the HVFA, the MMDT is a laptop-based test with 32 vertical line stimuli, each scaled by 
estimate of retinal ganglion cell density and selected using the Garway-Heath anatomical map 
(Loughman et al., 2013).  Whilst fixating at a central white dot monocularly, the patient is required to 
click on the mouse every time a movement of the vertical line is seen. Subjects who were unfamiliar 
with the concept of a mouse were given a short demonstration on the appropriate use of a left click. A 
test distance of 30cm was maintained and a near addition, appropriate to the patient’s age, was only put 
up during testing conducted with the HVFA (as the MMDT is resistant to optical blur and refractive 
error of up to +5.00D). One examiner performed testing on the HVFA and one performed the 
Moorfields MDT, under the same environmental conditions in separate rooms, in order to minimise 
inter-examiner variability. Only those subjects who yielded acceptable results (where reliability indices 
were within norms) were included in the data analysis. The two sets of values were then compared to 
determine the accuracy of the Moorfields MDT in detecting visual field defects in glaucoma subjects 




3.7 Data collection process: 
3.7.1 Data Analysis: The data was stored and computed using the Stata statistical software package 
version 14.1 software. Threshold results from the two tests were compared. The central zone (4 
locations within 3 degrees of fixation) was compared to the periphery (9-27 degrees from fixation) 
(Verdon-Roe et al., 2008). MMDT requires a global probability of true damage (PTD) of 3 or less and 
a false positive rate of 5% or less to ensure reliability (Loughman et al., 2013). The HVFA requires a 
false positive rate of 33% or less and a fixation loss value of 20% or less (Newkirk et al., 2006). 
However, Newkirk et al. (2006) report a false positive rate of 20% or more on the HVFA should be 
considered unreliable; therefore, this criterion was used in the analysis process (as opposed to 33%).  
 
The MMDT uses cluster analysis and tests 32 points while the HFVA tests 52 points. Correlating points 
(32) on the HVFA plot were selected while the rest of the points were disregarded. The sensitivity was 
investigated by doing a point-to-point comparison between the visual field defect points of the pass/fail 
plot on the MMDT and the probability plot on the HVFA.  Since the HVFA is regarded as the gold 
standard all the failed squares were counted, that is defects reflected by points (black squares on HVFA) 
with a probability index of p<0.5% on the HVFA and corresponding failed points on the MMDT plot 
were evaluated for agreement.  All those points that were agreeable with HVFA on the MMDT plot 
were counted. Those points that were failed on the MMDT but not on the HVFA were regarded as false 
positives, whilst all those points failed on the HVFA but not on the MMDT were regarded as false 
negatives.  
Given the MMDT ESTA version 99.5 corresponds to points on the HVFA central 24-2 program, the 
plots were compared by sector. To allow for improved comparison between the two instruments, the 
developers of the MMDT software are currently researching the relative dynamic range of each 
stimulus. (NHS trust: Moorfields eye hospital). The Shapiro-Wilk and Kolmogorov-Smirnova tests 
were used to test normality. As results were not normally distributed, the median test time was 
calculated for the case and control group for both the HVFA and MMDT. When assessing the diagnostic 
accuracy of a new test compared to the gold standard, the key areas of assessment include the sensitivity 
and specificity, as well as the positive and negative likelihood ratios (Florkowski, 2008). Sensitivity 
yields positive test results and refers to those participants who have the case condition. Specificity yields 
negative results and represents the portion of patients who do not have the case condition. Likelihood 
ratios (LR) are believed to be more intelligible to clinicians and allow for a more relevant interpretation 
of the test results. They can be separated into positive and negative likelihood ratios (+LR and -LR). 
Calculations to validate the MMDT included: 
• sensitivity and specificity of both case and control group 
• positive and negative likelihood ratios for both case and control group 
• positive and negative predictive values for both case and control group 
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The Mann-Whitney U Test was used to determine the distribution of average test duration amongst the 
two groups, gender and race, whilst the Kruskal-Wallis Test was used to determine duration of focus 
for the two instruments. Chi-square analysis and cross-tabs were used for the qualitative aspect of the 
study. These included subjects’ preference of fixation target and method of selection, preference of 
visual field instrument and level of anxiety using both instruments. 
 
3.7.2 Data management: All collected data was captured in a Microsoft Excel Spreadsheet daily. An 
optometrist independent to the study had validated 10% of the data entries to ensure minimal errors 
were made during capturing. The primary researcher, supervisors and statistician(s) had access to the 
data.  
 
3.8 Ethical considerations: 
Ethical approval was sought from the Biomedical Research and Ethics Committee (BREC) at UKZN 
(BE421/16) (Appendix 6) as well as KZN Department of Health (Reference: HRK289/16; 
KZ_2016RP47_13) (Appendix 7). Gatekeeper permissions were also obtained from management at 
both McCord Provincial Eye Hospital (Appendix 8) and Prince Mshiyeni Memorial Hospital (Appendix 
9). Each patient was provided with an information document in their preferred language (Appendix 1 
and 2), and once read and accepted, were requested to sign a consent form (Appendix 3 and 4) before 
participating in the study. All participants were ensured of their anonymity in their participation in the 
study and were given the option to withdraw from the study at any point if they needed to.  
Raw data was captured into a Microsoft Excel spreadsheet which is retained by the principal researcher.  
Raw data was stored safely in a locked cupboard and will remain there for five years at which point 
they will be destroyed and disposed of securely. The principal researcher and supervisors are the only 
people with access to the data. The data will be stored for a period of 5 years and thereafter ethically 
disposed of. 
 
This chapter discusses the procedures and protocols undertaken to conduct the study. It also highlights 
the measures taken to ensure reliable data collection. Unfortunately, due to time constraints of the 
hospital staff and participants, quality assurance could not be done daily and this is listed as one of the 





CHAPTER 4: Manuscript 1 
 
This chapter addresses the background of glaucoma in South Africa and the functional vision 
impairment that comes with the disease. Here we look at a new development in visual field testing, the 
Moorfields Motion Displacement Test (MMDT), and compare its level of agreement to that of the gold 
standard, Humphreys Visual Field Analyser, specifically in detecting glaucomatous visual field 
changes. 
This chapter may have a considerable amount of overlap with the content covered in Chapters 2 
(Literature Review) and 3 (Methodology).  
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Introduction Glaucoma, the third leading cause of blindness in Africa (after cataract), is responsible 
for approximately 15% of blindness in the continent. Generally, glaucoma goes undiagnosed in 
developing countries because of lack of awareness of the disease and its effects. The cost of standard 
methods for screening, including computerised perimetry (such as the gold standard Humphreys Visual 
Field Analyser), is not affordable and relatively inaccessible in most developing countries, posing a 
barrier to identifying people at risk for glaucoma blindness. The above factors initiated the development 
of more efficient, cost effective and portable visual field screening instruments, such as the Moorfields 
Motion Displacement Test (MMDT). 
 
Purpose The aim of this study was to assess the diagnostic accuracy, acceptability, and usability of the 
Moorfields Motion Displacement Test (MMDT) in comparison with the gold standard Humphreys 
Visual Field Analyser (HVFA) as a tool for community glaucoma screening. 
 
Method This was an observational, analytical study (involving comparative and quantitative methods). 
Ethical clearance was obtained from the Biomedical Research and Ethics commission at UKZN 
(BE421/16) as well as KZN Department of Health (Reference: HRK289/16; KZ_2016RP47_13).  The 
case group (glaucoma participants) were selected via chart review of those booked for visual fields at 
McCord’s Provincial Eye Hospital in KwaZulu-Natal (KZN), whilst the control group was selected via 
a chart review of participants booked for refraction at Prince Mshiyeni Memorial Hospital in KZN. 
Both eyes of the participant were tested, using both the HVFA and the MMDT. Threshold results from 
the two tests were analysed.  Point-to-point comparison using the Wilcoxon signed rank test was used 
to compare thresholds location-wise.  
   
Results A total of two hundred and seven subjects were tested of which, 94 eyes were diseased 
(glaucomatous) and 199 eyes non-diseased (control).  Sensitivity to detect glaucomatous visual fields 
amongst case and control subjects was 100% in both groups. Specificity of the test to detect 
glaucomatous visual fields amongst case participants was 65.3% and was similar to that of the control 
group (63.3%). The average time taken on the HVFA among case subjects was 394 seconds (±80sec) 
and that of the MMDT was 128 seconds (±29 sec), whilst the average times among control subjects 
were 387 seconds (±73 sec) and 131 seconds (±29 sec) for the HVFA and MMDT respectively.  
  
Discussion The sensitivity of the test to detect glaucomatous visual fields amongst case and control 
subjects was high and reflects the high ability of the MMDT in detecting glaucomatous visual field 
changes. Specificity of the MMDT was 63.0% for cases and 65.3% for the control group and, although 
lower than expected, indicates the ability of the MMDT to avoid overburdening the health care system 
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by reducing over-referrals. Test duration between the two instruments showed a superiority of the 
MMDT relative to the HVFA and this is highly beneficial to avoid inaccuracies due to patient fatigue. 
In addition, the faster test time allows for mass community glaucoma screenings, especially so in 
developing countries where access to health care is relatively limited.  
 
Conclusion The MMDT has yielded high sensitivity for both case and control subjects in detecting 
glaucomatous visual field changes (>75%), however, specificity was low (<85%). There is therefore a 
need to modify the current methods to yield higher specificity while maintaining sensitivity. The 
MMDT also proved to be approximately three times faster as compared to the HVFA making mass 
screenings easier, ultimately delivering high volume testing where it is accessible.  
 
 






Visual field screening tests are used when only the gross impact of disease on the visual field needs to 
be evaluated to rule out the presence of significant pathology. The purpose is not to perform a detailed 
evaluation of the visual field status (Elliott, 2013). The present methods for glaucoma screening are 
expensive and are a barrier to identifying people at high risk for glaucomatous disease compared to 
other ocular diseases (Quigley, 1996). Apart from the cost, most of the current methods of screening 
require a significant amount of testing time (Lawrence and Budenz, 2013) . If glaucomatous visual 
fields are left undiagnosed, treatment cannot be initiated and therefore many activities of daily living 
are increasingly affected as the disease progresses, including reading and writing, mobility and 
discrimination of colours (Taylor and Keeffe, 2001; Rong-jiang et al., 2011).  In addition, lack of 
management can lead to blindness with its consequent socio-economic effects (World Health 
Organisation, 2006).   
 
Visual field perimetry and developments in glaucoma detection tests 
Visual field perimetry is vital in detecting the functional loss that accompanies glaucoma (Nouri-
Mahdavi, 2014) as well as measuring the severity and progression of disease (Peters et al. 2015). These 
tests are subjective in nature and require the patient to understand the testing instruction, fully cooperate 
with the test requirements, and complete the entire test in order to provide accurate and reliable results 
(Alencar and Medeiros, 2011). An essential component for accurate diagnosis and implementation of 
appropriate management regimens is the reliability and repeatability of the visual field test (Newkirk et 
al., 2006).  Factors influencing the accuracy of visual field testing include refractive error, pupil size 
(Nussdorf and Alastair, 2003), ocular structural abnormalities (Alastair and Denniston, 2009) and 
intraocular stray light (Bergin et al., 2011). Patient profile and co-operation, defective instruments, the 
operator’s technical skill, as well as the testing environment, also contribute to the overall accuracy of 
test results obtained (Nussdorf and Alastair, 2003). 
 
The above factors initiated the development of more efficient, cost effective and portable visual field 
screening instruments, one of them being the Moorfields Motion Displacement Test (MMDT) 
(Moorfield’s Eye Hospital: NHS Foundation Trust, 2008). The MMDT is a multi-location test, 
presenting vertical line stimuli in 32 test locations on a computer screen; each scaled by estimate of 
retinal ganglion cell density and selected using the Garway-Heath anatomical map (Loughman et al., 
2013). It aims to determine the smallest perceptible positional displacement, with the displacement 
giving rise to the sensation of movement (Verdon-Roe et al., 2006). However, the accuracy of the 
MMDT in comparison to the HVFA has not yet been established.  Therefore, this study set out to 
compare the visual field defects, if any, obtained by the Moorfields MDT to that obtained with the 
HVFA in diagnosed glaucoma subjects, as well as to assess its acceptability, usability and patients’ 
level of anxiety during testing.   
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Rationale of the validating the MMDT 
The purpose of this study was to determine the similarity in findings, between both the MMDT and the 
HVFA in detecting visual field defects, its testing time, demographic influence on participant 
experience (including preferred method of selection and fixation target), preferred instrument as well 
as the participants levels of anxiety during testing on each instrument 
 
Methods 
Ethical clearance was obtained from the Biomedical Research and Ethics commission at UKZN 
(BE421/16) as well as KZN Department of Health (Reference: HRK289/16; KZ_2016RP47_13). The 
study was conducted at McCord Provincial Eye Hospital (Durban) and Prince Mshiyeni Memorial 
Hospital (uMlazi) areas of KwaZulu Natal province in South Africa.  Outcome measures included:  
sensitivity and specificity of the Moorfield’s MDT results in comparison to the HVFA.  After estimating 
the confidence intervals, the margin of error was found to be 12.2% for sensitivity (73.0%) and 8.2% 
for specificity (90.0%) (Baez et al., 1995).   
 
The data collection was carried out by myself for the first three weeks, whilst I trained two fourth year 
optometry students, two third year optometry students and one technical assistant over a period of six 
months from 8am to 12pm. The clinical procedures were carried out in two separate rooms to ensure 
that results were obtained independently of each other.  For the case group, the HVFA test was carried 
out by a final year optometry student in room 1 and MMDT was conducted by a final year optometry 
student in room two (Figure 4.1), whilst for the control group, the HVFA test was carried out by a third-
year optometry student in room one and MMDT was conducted by a third-year optometry student in 
room two.   
 
Data was collected from 12 December 2016 to 22 August 2017.  Access to daily patient files was used 
to recruit subjects diagnosed with glaucoma at MPH and PMMH. The total number of eyes tested for 
case and control participants were 352 and 618, respectively. Reliable data was obtained for a total of 
two hundred and seven participants, of which sixty-two were diagnosed with glaucoma and one hundred 
and forty-five without glaucoma. The total number of eyes included in the case group was ninety-four 
(94) and that of the control group was one hundred and ninety-nine (199), giving a total of two hundred 
and ninety-three (293) eyes being included in the study. Each participant had undergone ocular health 
assessment with an ophthalmologist prior to their visual field test. To assess the specificity of the 
MMDT, the age-matched control group was selected by accessing files of those patients at PMMH 
booked for refraction. Each participant was provided with an information document and consent form 
in their preferred language, following which a questionnaire was administered before and after testing 
on both instruments. Participants were randomised to which visual field test was conducted first. The 
results were captured daily in an excel spreadsheet and 10% of the data entry was verified by a third 
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party to ensure quality of the data entry process.  Data was exported into the Stata statistical software 
package version 14.1. Non-parametric analysis was conducted as results were not normally distributed.  




Figure 4.1. Flowchart of data collection procedure 
 
Results 
4.1 Demographic distribution  
The data obtained in this study were not normally distributed and verified by the Shapiro-Wilks test 
(Table 1) for gender, duration, and race P< 0.05, therefore non-parametric tests were used during 
analysis. The case group comprised of 62 participants (ninety-four eyes) (Figure 4.1), of which, 66.1% 
(n= 41), were females (Figure 4.2) with the most prevalent age group distribution ranging between 60-
69 years (Figure 4.3) with more than half (56.5%) being of Indian origin. The control group comprised 
of 145 participants (199 eyes) (Figure 4.1), of which, 64.8% (n= 94) were females (Figure 4.2), with 
the most prevalent age group distribution ranging between 40-49 years (31.7%) (Figure 4.3) and among 





Table 4.1. Table of tests of normality using Shapiro-Wilk test and Kolmogorov-Smirnova 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic Df Sig. Statistic df Sig. 
Dur*_MMD
T 
.100 199 .000 .937 199 .000 
Dur*_HVFA .119 199 .000 .932 199 .000 
Age .069 199 .022 .988 199 .079 
a. Lilliefors Significance Correction (applied when the Kolmogorov-Smirnova test is used to 
evaluate a sample size of under two thousand). 
* ‘Dur’ refers to test duration 
 
 




Figure 4.3. Distribution of age categories amongst case and control participants  
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4.2 Comparison of time taken using both HVFA and MMDT across different age groups 
Results reveal there is significant positive correlation between the age of participants and duration of 
HVFA (r = 0.270), and duration of MMDT (r = 0.347) at 1% (p<0.01) level. This implies, test duration 
appears to increase with age using the HVFA machine, with a direct relationship existing between test 
duration of the participants using the two machines. 
 
4.3 Median test time of case and control group 
As results were not normally distributed, the median test time taken for the case group with the MMDT 
was 128 seconds (±29 sec), approximately three times faster than that of the HVFA. The HVFA had a 
median test time of 394 seconds (±80 sec). The median test time taken for the control group with the 
MMDT among females was remarkably similar to that of males which was 131 seconds and 130 
seconds, respectively. Table 4.2 below shows the median test time across different age groups on both 
instruments, whilst Table 4.3 depicts the median test time across both the case and control groups. The 
median test time with the MMDT among the case group was similar with females taking an average of 
130 seconds and males 128 seconds. Among the age groups, the highest average test duration of 154 
seconds (±17 sec) occurred in the >80-year-olds category when using the MMDT, whilst the highest 
average time of 427 seconds (±90 sec), using the HVFA occurred in the 70-79-year-olds category. 
Those in the 40- 49-year age group performed the fastest overall on both instruments. For the case 
group, the shortest average test time of 123 seconds occurred among the 40-year-olds and under 
category. Those 80 years and older of the case group took an average test time of 154 seconds which 
was higher than that of the control group (149 seconds).  
 
Table 4.2. Table of median test times of the HVFA and MMDT amongst the different age groups 
 
 
Age Dur*_MMDT Dur*_HVFA 
<40 yrs 
N 9 9 
   
Median 0:02:00 0:05:34 
Std. Deviation 0:00:31 0:00:56 
Minimum 0:01:40 0:04:25 
Maximum 0:03:02 0:07:19 
40 - 49 yrs 
N 51 51 
   
Median 0:02:00 0:06:01 
Std. Deviation 0:00:29 0:01:05 
Minimum 0:01:31 0:04:26 
Maximum 0:03:23 0:09:13 
50 - 59 yrs 
N 50 50 
   
Median 0:02:08 0:06:25 
Std. Deviation 0:00:27 0:01:08 
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Minimum 0:01:33 0:04:54 
Maximum 0:03:31 0:10:13 
60 - 69 yrs 
N 59 59 
   
Median 0:02:06 0:06:19 
Std. Deviation 0:00:29 0:01:16 
Minimum 0:01:31 0:04:40 
Maximum 0:03:16 0:09:47 
70 - 79 yrs 
N 27 27 
   
Median 0:02:13 0:06:43 
Std. Deviation 0:00:32 0:01:30 
Minimum 0:01:31 0:04:51 
Maximum 0:03:34 0:10:23 
>= 80 yrs 
N 3 3 
   
Median 0:02:40 0:07:19 
Std. Deviation 0:00:17 0:01:27 
Minimum 0:02:15 0:05:26 
Maximum 0:02:48 0:08:18 
Total 
N 199 199 
   
Median 0:02:04 0:06:18 
Std. Deviation 0:00:29 0:01:15 
Minimum 0:01:31 0:04:25 
Maximum 0:03:34 0:10:23 





Table 4.3. Table of median test times of the HVFA and MMDT for the case and control group 
Group Dur*_MMDT Dur*_HVFA 
Glaucoma 
N 58 58 
   
Median 0:02:03 0:06:25 
Std. Deviation 0:00:29 0:01:20 
Minimum 0:01:31 0:04:25 
Maximum 0:03:09 0:10:23 
Control 
N 142 142 
   
Median 0:02:05 0:06:10 
Std. Deviation 0:00:29 0:01:13 
Minimum 0:01:31 0:04:37 
Maximum 0:03:34 0:10:19 
Total 
N 200 200 
   
Median 0:02:04 0:06:18 
Std. Deviation 0:00:29 0:01:15 
Minimum 0:01:31 0:04:25 
Maximum 0:03:34 0:10:23 
* ‘Dur’ refers to duration 
 
4.4 Median test time between males and females using HVFA and MMDT 
Females of the control and case groups using the HVFA had a higher total average test duration of 405 
seconds (±78 sec) and 406 seconds respectively, as compared to males who had a total average test 
duration of 362 seconds (±60 sec) and 370 seconds respectively. Males using the MMDT performed 
marginally faster than females on both instruments; 130 seconds (±27 sec) on MMDT, whereas females 
took a total average of 131 seconds (±30 sec). Similar to the MMDT, the highest average test duration 
(437 seconds) of the control group, occurred amongst the 70- 79-year-olds. The 80 year and above 





4.5 Validity of the MMDT 
4.5.1 Sensitivity and specificity  
The sensitivity of the MMDT to detect glaucomatous visual fields among the case and control group 
was high (>75%) 100.0%, with a low specificity (< 85%) of 63.3% and 65.3% for the case and control 
group respectively, as depicted in Table 4.4(a) and (b) below.  
 
 
Table 4.4a. Calculation of sensitivity and specificity amongst case subjects 








 TOTAL 𝑺𝒆𝒏𝒔𝒊𝒕𝒊𝒗𝒊𝒕𝒚 =  
𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆
𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆 + 𝒇𝒂𝒍𝒔𝒆 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆
 










 DX* 15 1/1 29 0/1 44 
NO DX* 0 1/0 50 0/0 50 
 TOTAL 15  79  94 
𝑺𝒑𝒆𝒄𝒊𝒇𝒊𝒄𝒊𝒕𝒚 =  
𝒕𝒓𝒖𝒆 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆
𝒕𝒓𝒖𝒆 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 +𝒇𝒂𝒍𝒔𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆
      
        =      
50
29+50
       
                     =   63.3% 
*DX stands for disease and is represented by values of one and above. 
1 represents diseased eyes; 0 represents non-diseased eyes 
 
Table 4.4b. Calculation of sensitivity and specificity amongst control subjects 








 TOTAL 𝑺𝒆𝒏𝒔𝒊𝒕𝒊𝒗𝒊𝒕𝒚 =  
𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆
𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆 + 𝒇𝒂𝒍𝒔𝒆 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆
 









 DX* 16 1/1 29 0/1 69 
NO 
DX* 
0 1/0 50 0/0 130 
 TOTAL 16  79  199 
𝑺𝒑𝒆𝒄𝒊𝒇𝒊𝒄𝒊𝒕𝒚 =  
𝒕𝒓𝒖𝒆 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆
𝒕𝒓𝒖𝒆 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 + 𝒇𝒂𝒍𝒔𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆
 
                      




                    =   65.3% 




Table 4.4(c) below shows the positive likelihood ratio was 2.7 and 2.9 for the case and control group 
respectively, whilst the negative likelihood ratio was 0 for both the case and control groups. 
 





































                                =   0.0 
 
Table 4.4(d) below shows the positive predictive value (PPV) of the test was 34.0% whilst the negative 
predictive value (NPV) was 100.0% amongst the case group. Whereas amongst the control group, the 
PPV of the test was 19.0% whilst the NPV was 100.0%. 
Table 4.4d. Calculation of positive and negative predictive value amongst case and control 
subjects  
 Cases Controls 
PPV    
𝑷𝑷𝑽 =
𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆









   
𝑷𝑷𝑽 =
𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆







































4.6 Average test duration comparison across the different age groups, race and gender:  
The Mann-Whitney U Test was used to determine the distribution of average test duration amongst the 
two groups, gender and race. The results show that the test duration for both the MMDT and HVFA 
machines did not differ significantly between the two groups of participants at 5% (p>0.05) level. The 
test duration also did not differ significantly between male and female participants using the MMDT 
at 5% (p>0.05) level. However, the duration of focus was significantly different at 5% (p<0.05) level 




Table 4.5a. Kruskal-Wallis Test to determine the distribution of average test duration amongst 
the 2 groups and race. 
 Null Hypothesis Test  Sig. Decision 
1 The distribution of Dur_MMDT is the same across 




0.501 Retain the null 
hypothesis 
2 The distribution of Dur_HVFA is the same across 




0.510 Retain the null 
hypothesis  
Asymptotic differences are displayed.  The significance level is 0.05. 
 
The Kruskal-Wallis Test reveals that the test duration for the two instruments was not significantly 
different among the three races at 5% (p>0.05) level.  
 
4.7 Chi-square analysis and cross-tabs for qualitative components of study: 
4.7a) Preferred method of selection among different race groups 
Participants were questioned as to which method of selection was preferred. The results revealed in 
Table 4.5b below indicate 84.8% of participants of Indian origin preferred mouse to button, 72.0% of 
participants of African origin preferred mouse to button, 66.7% of Caucasians preferred mouse to 
button whilst only the mixed race group preferred button to mouse, noting however, that there was only 
one participant of mixed race. Overall, 74.5% of the participants preferred mouse to button. However, 
the result of Chi-square analysis reveals that there was no significant variation at 5% (p>0.05) level in 
the distribution of the different races based on their preference for either mouse or button. 
 
Table 4.5b. Table of comparison of method of selection between mouse (MMDT) and button 
(HVFA) among the different race groups using Chi-square analysis 
 
 
Mouse_Button Total Chi-Square 
Value 
Df p-value 
Mouse Button    
Race 
Indian/Asian 39 (84.8%) 7 (15.2%) 46 (100.0%) 6.072 3 0.108 
African  108 (72.0%) 42 (28.0%) 150 (100.0%)    
Caucasian 2 (66.7%) 1 (33.3%) 3 (100.0%)    
 Mixed race 0 (0.0%) 1 (100.0%) 1 (100.0%)    





4.7b) Preferred method of selection between gender groups 
Table 5c below shows the result for gender and Mouse_Button cross-tabulation. The result reveals that 
73.2% of the males preferred the mouse to the button selector while 75.0% of the females preferred the 
mouse to the button. However, result of Chi-square analysis revealed that there was no significant 
variation at 5% (p>0.05) level in gender distribution based on their preference for either mouse or 
button. 
 
Table 4.5c.  Table of comparison between male and female participants of preferred method of 
selection between mouse (MMDT) and button (HVFA) using Chi-square analysis 
 Mouse_Button Total Chi-Square 
Value 
df p-value 
Mouse Button    
Gender 
Male 52 (73.2%) 19 (26.8%) 71 (100.0%) .092 1 0.762 
Female 97 (75.2%) 32 (24.8%) 129 (100.0%)    
Total 149 (74.5%) 51 (25.5%) 200 (100.0%)    
 
4.7c) Preferred visual field instrument among different race groups 
It can be deduced from Table 4.5d below that among the different race groups, 95.7% of participants of 
Indian origin preferred MMDT to HVFA, 80.7% of participants of African origin preferred MMDT to 
HVFA, 66.7% of Caucasians preferred MMDT to HVFA while only the mixed-race group preferred 
HVFA to MMDT, noting however, the mixed race group consisted of one participant whilst the 
Caucasian group consisted of three participants. Overall, 83.5% of the participants preferred MMDT to 
HVFA. Chi-square analysis reveals that the distribution of the different races based on their preference 
for either MMDT or HVFA varied significantly at 5% (p<0.05) level. 
 
Table 4.5d. Table of fixation stimulus comparison: Light (HVFA) and Dot (MMDT) using Chi-
square analysis  
 Light_Dot Total Chi-Square 
Value 
df p-value 
Dot Light    
Race 
Indian/Asian 39 (84.8%) 7 (15.2%) 46 (100.0%) 5.055 3 0.168 
African  120 (80.0%) 30 (20.0%)  150 (100.0%)    
Caucasian 2 (66.7%) 1 (33.3%) 3 (100.0%)    
Mixed race 0 (0.0%) 1 (10.0%) 1 (100.0%)    





4.7d) Preferred fixation target among different race groups 
Participants were also questioned as to which target of focus was preferred, and as can be deduced from 
Table 4.5d, 84.8% of participants of Indian origin preferred the dot to light, 80.0% of participants of 
African origin preferred the dot to light, 66.7% of Caucasians preferred the dot to light while the only 
mixed race group among the participants preferred the light to the dot, noting however that this group 
consisted of only one participant. Overall, 80.5% of the participants preferred dots to light. Chi-square 
analysis however revealed again that there was no significant variation at 5% (p>0.05) level in the 
distribution of the different races based on their preference for either the light or dot.  
 
4.7e) Preferred fixation target across gender groups  
Table 4.5e below shows the result for gender and Light_Dot cross-tabulation. The result revealed that 
74.6% of the males preferred the dot to light while 83.7% of the females preferred the dot to light. 
However, result of Chi-square analysis reveals that there was no significant variation at 5% (p>0.05) 
level in gender distribution based on their preference for either the light or dot.  
Table 4.5e. Table of comparison between male and female participants of preferred fixation 
target between dot (MMDT) and light (HVFA) using Chi-square analysis 




Dot Light    
Gender 
Male 53 (74.6%) 18 (25.4%) 71 (100.0%) 2.402 1 0.121 
Female 108 (83.7%) 21 (16.3%) 
129 
(100.0%) 
   
           Total 161 (80.5%) 39 (19.5%) 
200 
(100.0%) 
   
 
4.7f) Preferred visual field instrument among gender groups 
Crosstab (Table 4.5e above) also revealed 78.9% of the males preferred MMDT to HVFA while 86.0% 
of the females preferred MMDT to HVFA. Chi-square analysis however reveals that there was no 
significant variation at 5% (p>0.05) level in gender distribution based on their preference for either 
MMDT or HVFA. 
 
4.7g) Preferred visual field instrument among age groups  
The result reveals that 55.6% of participants whose ages are less than 40 years preferred MMDT to 
HVFA, 84.3% of those who fall within age group 40 – 49 years preferred MMDT to HVFA, 92.0% of 
those within age group 50 – 59 years preferred MMDT to HVFA, 79.7% of those within age group 60 
– 69 years preferred MMDT to HVFA, 85.2% of those within age bracket 70 – 79 years preferred 
MMDT to HVFA while 100.0% of those whose ages are 80 years and above preferred MMDT to 
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HVFA. Result of Chi-square analysis, however, reveals that the distribution of the participants’ 
preference for either MMDT or HVFA across different age groups did not vary significantly at 5% 
(p>0.05) level. 
 
4.7h) Preferred method of selection among age groups  
The results below (Table 4.5f) depict cross-tabulation for age group and Mouse_Button. The result 
reveals that 77.8% of participants whose ages are less than 40 years preferred mouse to button, 72.5% 
of those within age group 40 – 49 years preferred mouse to button, 82.0% of those within age group 50 
– 59 years preferred mouse to button, 67.8% of those within age group 60 – 69 years preferred mouse 
to button, 77.8% of those within age bracket 70 – 79 years preferred mouse to button while 100.0% of 
those whose ages are 80 years and above preferred mouse to button. Result of Chi-square analysis 
however reveals that the distribution of the participants’ preference for either mouse or button across 
different age groups did not vary significantly at 5% (p>0.05) level. 
 
Table 4.5f. Table of comparison of preferred method of selection between mouse (MMDT) and 
button (HVFA) among the different age groups 
 Mouse_Button Total Chi-Square 
Value 
df p-value 
Mouse Button    
Age 
<40 yrs 7 (77.8%) 2 (22.2%) 9 (100.0%) 4.235 5 0.516 
40 - 49 yrs 37 (72.5%) 14 (27.5%) 51 (100.0%)    
50 - 59 yrs 41 (82.0%) 9 (18.0%) 50 (100.0%)    
60 - 69 yrs 40 (67.8%) 19 (32.2%) 59 (100.0%)    
70 - 79 yrs 21 (77.8%) 6 (22.2%) 27 (100.0%)    
>= 80 yrs 3 (100.0%) 0 (0.0%) 3 (100.0%)    




This study stemmed from an unpublished pilot study which was conducted in 2012 by undergraduate 
students at the University of KwaZulu Natal, Westville Campus, in which, the accuracy of the 
Moorfield’s Motion Displacement tester (MMDT) was evaluated.  The study followed a quantitative 
cross-sectional design, comprising participants from the St Aidan’s Hospital eye clinic booked for 
visual field testing.  A total number of 260 eyes were assessed using both the Humphrey’s Visual Field 
Analyser and the MMDT. The SITA central 24-2 threshold test was used on the HVFA and the ESTA 
99.5 suprathreshold test was used on the MMDT. These two tests allow point to point comparison of 





Using ROC analysis, the sensitivity was found to be 83.18% with a standard deviation of ±7.6% (95%CI 
75.6%-90.76%), slightly below acceptable sensitivity of 85.7%. (These results however, showed higher 
sensitivity compared to the findings of Baez et al. (1995) who found a sensitivity of 73.0% with the 
MMDT compared to the HVFA).  Due to a small sample size, specificity was not found. 
The level of agreement showed correspondence between the actual field defect points on the MMDT 
with the HVFA. A high level of agreement in about 50% of the sample was indicated, however, was 
not significant enough to show that the instrument can be used as a diagnostic tool.  It was also found 
that the mean testing time with the MMDT is 4.3 times faster than with the C24-2 on the HVFA (t-test 
for unequal variances, p=0.000).  The study concluded that the MMDT’s cost and portability, and its 
measured sensitivity and short testing time, indicate that it is a viable vision screening tool in the context 
of a developing world, however, its accuracy to be used as a diagnostic tool has not yet been established.  
Furthermore, the lack of a control group and small sample size, did not allow all relevant objectives to 
be measured. 
 
The case group in our study comprised 66.1% females (n= 41), with the most prevalent age group 
distribution ranging between 60-69 years and the highest prevalence occurring in the Indian population 
(56.5%). This is a consequence of non-random sampling influenced by the patient demographic of 
MPH. It therefore goes against the literature which states that glaucoma is most prevalent among those 
of African origin (Loughman et al., 2013; Weinreb et al. 2014), however, is consistent with research 
that states the onset of disease mostly presents in those 50 years and older (Brusini et al., 2005). The 
control group comprised 64.8% females (n= 94), with the most prevalent age group and racial 
distribution ranging between 40- 49 years among the African population. Again, this racial distribution 
could be attributed to the majority of people being of African origin and attending the eye clinic at 
PMMH. According to a study investigating health care utilization in South Africa, this result might also 
be attributed to the health-seeking behaviour of females, who are approximately twice as likely to seek 
health care as compared to males (Abaerei et al. 2017).  
 
The average test time taken for the case group with the MMDT was 128 seconds (±29), approximately 
3 times faster than that of the HVFA, which was an average of 394 (±80) seconds and is consistent with 
the literature which states the MMDT Enhanced Supra-Threshold Strategy (ESTA) takes an average 
test time of 90-120 seconds per eye (Bergin, 2011). This is an important finding given that this device 
has been designed for fast and reliable community based screening (Shekhar and Xiong, 2008). Given 
the general lack of access to eye care service in most developing countries, the efficiency of the MMDT 
provides a commendable platform for prospective glaucoma screening programmes (Loughman et al., 
2013). From a clinical perspective, the advantage of reduced test time directly impacts on reducing 
patient fatigue, thereby increasing the reliability of results (Dersu et al., 2006; Patyal et al., 2014). The 
advantages of faster test time will also include the ability to create bridging mechanisms between 
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communities and eye care facilities (Melese et al., 2004), as well as a greater screening success for 
those who would require follow up testing (McManus and Netland, 2013). For the MMDT, the highest 
average test duration of 149 seconds occurred in the 70- 79-year-old category of the control group and 
those 80 years and older of the case group took an a slightly higher average test time of 154 seconds. 
The reasoning behind this result could be attributed to the general decline in gross and fine motor skills, 
as well as dexterity in older individuals (Voelcker-Rehage, 2008).  As people age, performance of 
complex tasks occurs more slowly and, in some cases, less accurately than they once did, however, 
although motor performance tends to decline in old age, learning capabilities remain intact (Voelcker-
Rehage, 2008).     
 
Sensitivity of the MMDT in detecting visual field changes in both the case and control group was 
excellent, yielding 100% in both groups. The sensitivity was much higher than that found in the Tajimi 
study, where Frequency Doubling Technology (FDT) perimetry was found to have a low sensitivity 
(55.6%) when diagnosing glaucoma (and/or retinal disease) thereby limiting its ability in screening the 
general population (Boland et al., 2016). Specificity of the test to detect glaucomatous visual fields 
amongst case subjects was 63.3% and was similar to that of the control group (65.3%). 
 
The positive predictive value (PPV) for the case and control group were 34% and 19% respectively. 
These values are most likely as a result of a large number of false positives, therefore a positive result 
on the MMDT alone is poor in indicating the presence of glaucoma, which warrants further testing to 
confirm a diagnosis. Despite a test displaying a good sensitivity and specificity, the occurrence of a low 
PPV is still possible if the test has been conducted in a population where the disease likelihood is low 
(Ranganathan and Aggarwal, 2018). The MMDT did however yield a high sensitivity of 100% in both 
the case and control groups and is highly beneficial in a developing world context as this instrument 
proves to be successful in detecting glaucomatous visual field changes and will aid in mass screenings 
in the community. This study is not primarily a screening evaluation, however, it enabled us to evaluate 
the performance of the MMDT in screening for glaucomatous changes. The negative predictive value 
(NPV) for both case and control subjects was 100%. This is highly useful as it scientifically proves the 
MMDT will avoid the case of false negatives, thereby reducing the risk of under referrals and 
misdiagnosing those patients who actually have glaucoma, requiring appropriate medical attention 
(Saunders et al., 2015).The above results show that the MMDT correctly identified 65.3% (specificity) 
of those who did not have glaucomatous visual field changes.  
 
When assessing the usefulness of a diagnostic instrument, the calculation of positive and negative 
likelihood ratios is of more clinical significance (Akobeng, 2007). These ratios determine by how much 
more (or less) likely participants with a disease will present with a particular result than participants 
without a disease and is a combination of the sensitivity and specificity (Akobeng, 2007). In this study, 
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the positive likelihood ratio (+LR) for the case and control groups were similar, yielding 2.72 and 2.86 
respectively, with a negative likelihood ratio (-LR) of 0 for both groups. The +LR of 2.72 indicates an 
approximate increase in probability of just over 15% that the MMDT detects positive results of 
glaucomatous visual field change. In contrast, the -LR of 0, shows a large decrease (approximately 
45%) in probability of the presence of glaucomatous visual field changes. These results differ when 
compared to the findings of Ong et al., (2014) who found the +LR to be 12.1 at a sensitivity of 87.2%, 
whilst the -LR was 0.14 at a specificity of 92.8%. Although research states that a feasible diagnostic 
test offers a high +LR and a low -LR (Ong et al., 2014), the most significant ratios are those <0.1 or 
>10 as they have the largest effect on post-test probability (Shah et al., 2006).  
According to Shah et al., (2006), likelihood ratios between 0.5 and 2 have an insignificant effect on the 
post-test probability of disease, whilst those between 0.2 and 0.5 have a small effect on post-test 





Conclusions and recommendations 
The results from this study indicate there is a high level of agreement between the MMDT and the 
HVFA, both in detecting visual field changes in diseased (glaucomatous) eyes, as well as non-diseased 
(control) eyes.  Scientifically proven to be faster than the HVFA (approximately three times), the 
MMDT has the added advantage of being more portable and cost-efficient. This is extremely useful in 
a developing world context since access to basic health care facilities is relatively limited. By 
introducing such instruments, mass screenings become readily approachable, thereby allowing for 
earlier detection, diagnosis and management of glaucoma. Mass screenings of ocular diseases, such as 
glaucoma, can in turn aid in the reduction of patients affected by avoidable blindness. The MMDT has 
now proven to be scientifically more likely than FDT perimetry in screening for glaucoma in the 
population-based setting and our results are consistent with the findings of (Ong et al., 2014) who also 
concluded the MMDT can be used as a diagnostic tool. 
 
Due to the irreversible effects of glaucoma, many patients affected by this disease often end up with the 
resultant socio-economic effects and overall quality of life being reduced.  As it is a disease which 
presents mostly in older individuals (40 years and older), these patients often have to deal with much 
more than just ocular difficulties. These include mobility and dexterity issues, hearing loss, memory 
loss, coupled with driving inability and visual search issues. As patients experience an increase in the 
loss of vital senses, they become more dependent on family, friends and/or caregivers which eventually 
has a resultant effect on their self-esteem.  These difficulties are quite evident in those patients who 
struggle with the impending challenges of low vision.  
 
Another challenge in developing countries is the availability of optometrists and ophthalmologists, 
more especially in the public sector. There is a large ratio of patients to a single ophthalmologist and to 
perform further investigations on patients becomes difficult and is exacerbated when these tests are time 
consuming (such as the HVFA). In South Africa, the ratio of optometrists to the population is 
approximately 1:17600 (Naidoo, 2007). It is recommended for future studies and developments, that   
the above factors are considered in order to improve on current technology and systems in the field of 
eye health care, specifically to that which is required for visual field testing. It is also recommended 
that similar research is conducted on a larger sample size as well as on conditions other than glaucoma 
to determine if the instrument can be applicable to all kinds of visual field changes. In order to improve 
on the specificity from this study, age-matched controls as well as repeat tests on abnormal results are 
recommended. In addition, our study had not specified predefined levels of glaucoma severity which 
could be an essential criterion when assessing the efficacy of the MMDT to monitor the progression of 
glaucoma and other visual field defect-causing abnormalities. The stringency of the screening test could 
be altered to adjust the PPV and NPV to a desirable level. This could be done by raising the cutpoints 
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of the reliability indices on both visual field instruments or by performing the screening on those with 
moderate to advanced glaucoma only (Ranganathan and Aggarwal, 2018).  
Unfortunately, there is currently no global indices such as mean deviation (MD) or pattern standard 
deviation (PD) available to accurately analyse the visual field defects as the MMDT is a suprathreshold 
test, however, the MMDT is certainly scientifically proven to be sensitive enough in screening 
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CHAPTER 5. General synthesis, conclusions and recommendations 
 
5.1 General synthesis 
This chapter may have a considerable amount of overlap with information from chapter 2 (literature 
review), chapter 3 (methodology) and chapter 4 (manuscript 1). 
The overall aim of the study was to determine the similarity of visual field findings between the HVFA 
and Moorfields MDT. The findings of this study suggest that the MMDT is a viable alternative for use 
in screening visual field changes in glaucoma patients. This is reflected by the specificity of 63.3% and 
sensitivity of 100%.  The findings are in accordance with Ong et al. (2014) who also suggests that the 
instrument provides good diagnostic performance in identifying glaucomatous eyes and shows potential 
as a new diagnostic tool. The MMDT is portable, faster, accessible and relatively cost effective thereby 
validating its use in a developing world context (Ong et al., 2014).  
The sensitivity found in this study (100% for both the case and control groups) was much higher than 
that found in the Tajimi study, where Frequency Doubling Technology (FDT) perimetry was found to 
have a low sensitivity (55.6%) when diagnosing glaucoma (and/or retinal disease) thereby limiting its 
ability in screening the general population (Boland et al., 2016). Specificity of the test to detect 
glaucomatous visual fields amongst case subjects was 63.3% and was similar to that of the control group 
(63%). There is therefore a need to modify the current methods to yield higher specificity while 
maintaining sensitivity. One particular study by Heeg et al. (2005) investigated strategies to improve 
the specificity of the FDT. It was found that the most effective strategy included confirming an abnormal 
test result with a repeat test, yielding an increase in specificity with some loss in sensitivity in the early 
to moderate glaucoma patients (Heeg et al., 2005). In 2003, Horn et al. also suggested that combined 
use of techniques proved to be more superior as opposed to just one method (Heeg et al. (2005). Heeg 
et al. (2005) suggested this strategy was not very useful and also deviates from the common clinical 
setting as it requires a second piece of equipment to be purchased.  
 
The NPV calculated at 100% also emphasises the value of the instrument in being able to produce less 
false positive findings.  This can have significant implications for resource limited settings where there 
is a significant paucity of human resources to address eye care needs.  Less false positive findings during 
screening of glaucomatous change will mean that less time is wasted on having to provide conclusive 
‘gold standard’ testing using the HVFA.  Furthermore, in settings where financial resources and 
infrastructure are limited, conclusive findings could be impossible if there is no HVFA. In some cases, 
patients may incur hefty costs in travelling to sites with the appropriate equipment to make conclusive 
diagnoses of potentially blinding glaucomatous change.    
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The negative predictive value (NPV) for both case and control subjects was 100%. This is highly useful 
as it scientifically proves the MMDT will avoid the case of false positives and thereby reducing over 
referrals- which essentially overburdens the health care system (Kaur et al., 2016). The above results 
show that the MMDT correctly identified 65.3% (specificity) of those who did not have glaucomatous 
visual field changes.  
 
 




The study concluded that the Moorfields Motion Displacement Test (MMDT) is sensitive enough 
(100%) in detecting visual field changes of diseased (glaucomatous) and non-diseased (control) eyes, 
when compared to the gold standard Humphreys Visual Field Analyser (HVFA). In a developing world 
context where resources are limited, the MMDT has the added advantage of being portable, inexpensive 
and faster (approximately 3 times), which is necessary for rapid case-finding in a community. The 
MMDT has now proven to be scientifically more likely sensitive than Frequency Doubling Technology 
(FDT) perimetry in screening for glaucoma in the population-based setting and our results are consistent 
with the findings of Ong et al. (2014), however, our study shows the instrument to be sensitive enough 
to be used as a screening tool due to its low specificity (63.3%).  
 
The results from this study showed no significant association between gender, age and race with regards 
to the test duration on both the MMDT and HVFA. Whilst there was no significant variation amongst 
the different gender and age groups when choosing a preferred visual instrument, 83.5% of participants 
across the different race groups, preferred the MMDT. There also seemed to be no significant variation 
among the different race, gender and age groups in selecting the preferred fixation target between the 
light (HVFA) or dot (MMDT) nor the method of selection using the button (HVFA) and mouse 
(MMDT). Overall the results did not indicate any significant anxiety between the associated groups 




Glaucoma generally affects older individuals, who often have to deal with more than just ocular 
challenges, such as mobility and dexterity issues, hearing loss, memory loss, coupled with driving 
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inability and visual search issues. The availability of optometrists and ophthalmologists in the public 
sector is another challenge in developing countries with a large ratio of patients to a single practitioner, 
thereby making it even more difficult for follow up testing, more especially when tests are of longer 
duration and expensive to purchase and maintain (such as the HVFA). It is therefore recommended for 
future studies and developments, that the above factors are considered in order to improve on current 
technology and systems in the field of eye health care, specifically to that which is required for visual 
field testing.  The findings of the study suggest that the MMDT can be successfully used as a screening 
tool for visual field changes accompanying glaucoma.  It is recommended that similar research is 
conducted on a larger sample size as well as on conditions other than glaucoma to determine if the 
instrument can be applicable to all kinds of visual field changes. An adjustment to the referral criterion 
may remove the need for repeat testing. To optimise the reliability of test results, the study investigators 
would recommend that a custom designed and simple push button response system, that would require 
less manual dexterity and coordination, should replace the mouse in future versions of the test. 
 
 
5.2.3 Limitations of the study 
During the conduct of the study there were a few challenges which arose. At initial stages of data 
collection, recruitment of the desired number of participants per day were difficult to obtain, purely due 
to administrative processes at the location. This essentially meant fewer participants were tested per 
day, lowering the weekly target required. Another challenge encountered during the data collection 
process was the recruitment of control participants, as majority of the participants attending McCords 
Provincial Hospital had already presented with pathology. The location was then changed to Prince 
Mshiyeni Memorial Hospital to obtain the control participants. 
Due to time constraints, the recommended sample size was not obtained for both the case and control 
groups, and therefore, should be considered for future studies.  
 
The Moorfield’s Motion Displacement Test is relatively new when compared to the gold standard, 
Humphreys Visual Field Analyser and therefore no algorithm had yet been developed (at the time of 
this study) to directly compare the results from these two instruments. As a result, cluster analysis was 
done to ensure a clinically and statistically acceptable comparison. The format of choice was manuscript 
format, and including one article to summarise the best findings of the study also proved challenging. 
The structure could have been reconsidered to allow for more of the findings to be included in the 
dissertation, perhaps even in an additional article. 
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Appendix 1. Information document- English version 
INFORMATION DOCUMENT 
Study title: An evaluation of the accuracy of the Moorfield’s Motion Displacement Test 
Greeting: Dear Participant 
Introduction: I, Keshia Chetty, am conducting a research study on a recently developed visual field 
tester known as the Moorfields Motion Displacement Test (MMDT). The aim of the study is to compare 
the results from the Moorfields MDT to the tried and tested method which is the Humphreys Visual 
Field Analyser (HVFA). These devices are used to detect whether any changes occurring inside the eye, 
as a result of glaucoma, are affecting your awareness of your surroundings. The HVFA has been thought 
to be the best at detecting subtle changes in one’s visual field.  However, the Moorfields MDT is more 
affordable and if found to be as accurate as the HVFA, can be used as an alternative, especially in 
developing countries. For this reason, this study is of particular importance to us as it could provide our 
public health care system with a cost effective method of diagnosing glaucoma. 
Invitation to participate: We are inviting you to participate in this research study which has the potential 
to help millions of other people with glaucoma. 
What is involved in the study: By being part of this study you are agreeing that both eyes be tested, 
using both instruments. 
Risks: There are no potential risks of being involved in the study. You will not be identified. 
Benefits: The benefits involved are a comprehensive, free analysis of your visual field and knowledge 
of the quality of sight. 
Treatment: No treatment is required, however, if we do pick up any additional eye problems, we will 
advise you on possible steps to take. 
Reimbursements: There is no cost to be a participant in this study. 
Confidentiality: Efforts will be put in place to keep personal information completely confidential. 
Organizations that may inspect and/or copy your research records for quality assurance and data 
analysis include groups such as the Research Ethics Committee and the Medicines Control Council.  
All information will be kept confidential and kept in a locked cupboard for 5 years, after which they 
will be destroyed.  Your participation in this study is completely voluntary and a refusal to participate 
will involve no penalty. You may discontinue your participation from this study at any time.  
For further information, please contact: 
 
Miss Keshia Chetty: 074 303 5532  kbchetty.za@gmail.com 




Appendix 2. Information document- isiZulu version 
INFORMATION DOCUMENT (ZULU VERSION) 
UMBHALOOQUKETHEULWAZI 
Ukucwaningango kuthiumshini i-Moorfields motion displacement tester usebenza ngokunembayona 
ngobuchuleyini 
Kuwe ozobayinxenye yocwaningo: 
Isingeniso: 
Mina, ngiKeshia Chetty, senza ucwaningo ngomshini wokuhlola amehlo omusha i-Moorfields 
MDT,siwuqhathanisa ukusebenza kahle kwawonalo omdala owaziwange-Humphrey’s visual field 
analyzer (HVFA). Lemishini isetshenziselwa ukuhlola ukuthi ushintsho olwenzeka phakathi ehlweni 
ngenxa yezifo ezinjenge-Glaucoma luyayiphazamisa yini indlelaobonangayo, isibonelo: ukukwazi 
nokuqaphela indawo ukuyo. Lo omdala i-HVFA, ubusucwaningwe isikhathi esidewathwalwa ngeqoma 
njengo sebenza kahlengo kwedlulele. Kulolucwaningo sizo qhathanisa ukuthi i-Moorfields MDT  
isebenza kancono yinikune-HVFA.  Umshini i-Moorfields MDT ushibhilekune-HVFA ngakho-ke 
ungasiza emazweni asathuthuka ashodayo ngezinsiza.  Ukuhlola ubuchule be-Moorfields MDT 
sizohlola abane-Glaucoma. 
Isisimemo sokubayingxenye yocwaningo: 
Siyakumema ukuba uzibanda kanye nalolucwaningo. 
Yini engizoyenza ocaningweni: 
Uma uzibanda kanye kusho ukuthi uyavuma ukuhlolwa amehlo womabili kusetshenziswa imishini 
yomibili. 
Ubungozi: 
Abukho ubungozi ubuyobakhona, noma ubuyo bangumthelela wokubamba iqhaza noma ingxenye 
yogcwaningo.  Umbono wababambe iqhaza uyogcinwa uyimfihlo, kodwa umphumela wamaqembu 
uyosakazwa,  waziwe izwelonke.  Lokhu kuhlolwa ngeke kuwalimaze amehlo noma indlela obona 
ngayo ngakho-ke ucwaningo alukubeki engcupheni. 
Uzosizakala ngokuhlolwa amehlo mahhala nokwazi ukuthi ukubona kwakho kusezingeni elihle yini. 
Isimo sezokukhokha: 
Akukho mali ozoyikhokha.  
Imfihlakalo: 
Lonke ulwaziluzo gcinwa luyimfihlo ngaphandle uma lufunwa yingalo yomthetho. Ukuzibanda kanyak 
uzoba ukuthanda kwakho kanti ungayeka noma nini uma uthanda futhi ngeke uhlawuliswe 
ngokwenzenjalo. 
Thola imininingwane egcwele ngokuthintana no: 
Miss Keshia Chetty: 074 303 5532  kbchetty.za@gmail.com 
Miss P Govender:    031 202 3811  p.govender@brienholdenvision.org.za  
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Appendix 3. Consent form- English version 
CONSENT FORM (ENGLISH VERSION) 
Research Study: An evaluation of the Moorfields Motion Displacement Tester 
Dear Sir/Madam 
Glaucoma is a condition in which a patient is very often diagnosed with an increase in the pressure 
inside the eye.  This causes damage to the optic nerve found at the back of the eye, resulting in decreased 
awareness of one’s surroundings.  This affects many activities of daily living such as, difficulty reading 
and writing, moving around and difficulty seeing colours.  If left untreated, glaucoma can lead to 
blindness.  Since glaucoma is a condition which causes subtle changes in the visual field of the effected 
individual, we thought it pertinent to assess how accurate the new instrument, used for assessing visual 
fields, is in detecting these subtle changes.  
The Moorfields Motion Displacement Test (MMDT) and the Humphrey’s Visual Field Analyser 
(HVFA) are used to test how aware one is of their surroundings. The aim of this study is to investigate 
how accurate the Moorfield’s MDT is in comparison to the tried and tested Humphrey’s Visual Field 
Analyser (HVFA). 
You will be required to sit through both visual field tests, i.e. MMDT and HVFA.  During the eye 
examination, each of your eyes will be tested using both visual field tests.  The approximate test duration 
for the HVFA is 15 minutes for each eye, and for the Moorfields MDT, 5-7 minutes per eye.  The results 
will then be compared.  During the process, should we find any additional problems related to your 
eyes, we will advise you of possible steps you can take to address them.  The equipment used will not 
cause any pain or harm to your eyes or your vision in any way.  Your personal details will be kept 
confidential although results from the test will be analysed.  You have the right to withdraw from the 
study at any point during the examination should you wish to do so. 
If the above is understood and you agree to participate in this study, please sign in the space provided 
below.  By signing this document, you are agreeing to grant us permission to analyse and compare the 
results obtained from each test. 
The research will be conducted by myself, Keshia Chetty, with permission from the Medical Research 
Office at the Nelson R Mandela School of Medicine. This study is being supervised by Ms. P. Govender 
(Brien Holden Vision Institute), Prof. Kovin Naidoo (Department of Optometry at the University of 
KwaZulu Natal), and Prof. James Loughman from The Dublin Institute of Technology. 
______________________                                              ______________________ 
Patient                                                                                 Date 
______________________                                                 ______________________ 




Appendix 4. Consent form- isiZulu version 
 
CONSENT FORM (ISIZULU VERSION) 
IFOMU LOKUVUMA UKUBA YINXENYE YOCWANINGO 
Mnumzane/Nkosikazi/Nkosazana:  
Isifo esaziwa ngokuthi yi-glaucoma yisifo lapho kuba nengcindezi phakathi ehlweni bese kulimala 
umthambo omkhulu obizwa ngokuthi yi-optic nerve engemuva kwehlo. Lokhu kukhinyabeza 
ukusebenza kwehlo, kunciphe amathuba okubona okwenzeka endaweni okuyo. Lokhu kuphazamisa 
okuningi empilweni yomuntu yansuku zonke njengobunzima bokufunda nokubhala, ukuhamba 
okujwayelekile kanye nokuhluleka ukubona imibala. Ngakho-ke, uma ingalashiwe i-glaucoma ingenza 
umuntu agcine eyimpumputhe.  
Inhloso yalolu cwaningo ukuphenya ukuthi umshini omusha owaziwa nge-Moorefield’s MDT 
unobuchule nobuchwepheshe kangakanani uma uqhathaniswa nenhlobo endala eyaziwa ngokuthi yi-
Humphrey’s Visual Field Analyzer. 
Ngesikhathi kuhlolwa amehlo, ihlo lakho ngalinye lizohlolwa kusetshenziswa imishini yomibili ukuze 
kuqhathaniswe ukuthi imiphumela etholakalayo iyefana yini. Ukusetshenziswa kwale mishini ngeke 
kuwalimaze amehlo akho nokusebenza kwawo. Igama lakho nemininingwane yonke yakho izogcinwa 
iyimfihlo kodwa. Uma ufisa ukunyomuka ungabe usaba yinxenye yocwaningo unelungelo 
lokwenzenjalo noma nini.  
Uma uluqondisisa lolu lwazi olunikwe ngenhla futhi uzivumela ngokwakho ukuba yinxenye 
yocwaningo uzosayina esikhaleni esinikwe ngezansi. Lolu cwaningo luzobe lwenziwa uKeshia Chetty 
ngemvume yophiko lokucwaninga ngezempilo enyuvezi olwaziwa nge-Faculty of Health Sciences 
Research and Ethics committee. 
__________________       ___________________ 
Igama nesibongo        Usuku 
 
__________________       ____________________ 
Owezempilo          Ufakazi 
 
UKZN Eye Clinic (E5-525): 031 260 7352 
Medical Research Office @ Nelson R Mandela School of Medicine:  




Appendix 5. Data collection form   
Surname: Date: 
First Name:  Patient number:  
 
Age:      Gender:  




                    
      Number of years diagnosed with glaucoma:  
 
 
Please tick the correct choice with black ink only.  
*Question 12-16 to be answered at the end of the examination. 
Ocular history:  
1. When was your last eye examination?  
≤ 1 month ago  ≤ 1 year ago  ≥ 2 years ago  ≥ 5- 10 years ago  
 
  2. Did your last eye examination include a visual field assessment?  
Y N 
 
3.(a) Have you previously been diagnosed with any eye disease other than glaucoma?  
Y N 
 
(b) If you have answered “yes” to the above question, please specify. 
 
 
Y Y Y Y M M D D  
    
M F  
POAG PACG SOAG SACG 
INFANTILE 
PCG 







 (c) If you have answered yes to the previous question, please specify what treatment        











5. Which of the following systemic illnesses, if any, do you have? 
Diabetes  
Hypertension  
Thyroid disease  
Autoimmune disease  
Other  
None  
   











7. Is there a family history of glaucoma? 
Y N 
  
Question 8 and 9 are multiple response questions i.e. more than one choice can be ticked. 
8. Which activities of your daily living would you say have been affected since your glaucoma 
diagnosis?  
Mobility  
Driving   
Visual search  
 






Neutral   
 
 




11. On a scale of 0 to 5, (0= no anxiety; 5= extreme anxiety), please rate your anxiety levels during 










*12. To be answered at the end of the examination 
On a scale of 0 to 5, (0= no anxiety; 5= extreme anxiety), please rate your anxiety levels during visual 
field testing on the Moorfield’s Motion Displacement Test (MMDT): 
  
 
*13. To be answered at the end of the examination 
How would you rate the ease of use of the MMDT, as compared to the HVFA? (0= extremely difficult; 





*14. To be answered at the end of the examination 
Please select which method of response indication was easier to use between the HVFA and the MMDT 
(please tick appropriate choice): 
Push button on HVFA  Mouse on MMDT  
  
*15. To be answered at the end of the examination 
Between the two methods of visual field testing (which you were exposed to) which fixation target did 
you prefer? 
The central white dot of the MMDT  
















*16. To be answered at the end of the examination 
Between the two methods of visual field testing (which you were exposed to) which method (HVFA or 






























Appendix 10. Timeframe 
 
 
 
 
